{"title": "Cisplatino y quimioterapia combinada en el tratamiento de ni\u00f1os y adultos j\u00f3venes con hepatoblastoma o c\u00e1ncer de h\u00edgado despu\u00e9s de la cirug\u00eda", "author": null, "url": "https://ichgcp.net/es/clinical-trials-registry/NCT03533582", "hostname": "ichgcp.net", "description": "Este ensayo de fase II/III parcialmente aleatorizado estudia qu\u00e9 tan bien funciona el cisplatino y la quimioterapia combinada en combinaci\u00f3n con cirug\u00eda en el t.... Registro de ensayos cl\u00ednicos. ICH GCP.", "sitename": "ichgcp.net", "date": "2018-05-11", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Cisplatino y quimioterapia combinada en el tratamiento de ni\u00f1os y adultos j\u00f3venes con hepatoblastoma o c\u00e1ncer de h\u00edgado despu\u00e9s de la cirug\u00eda\n[Children's Oncology Group](https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Children%27s%20Oncology%20Group)\nEnsayo Terap\u00e9utico Internacional de Malignidad Hep\u00e1tica Pedi\u00e1trica (PHITT)\nDescripci\u00f3n general del estudio\nEstado\nCondiciones\nIntervenci\u00f3n / Tratamiento\n-\n[Otro: An\u00e1lisis de biomarcadores de laboratorio](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Laboratory%20Biomarker%20Analysis)\n-\n[Droga: Carboplatino](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin)\n-\n[Droga: Etop\u00f3sido](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Etoposide)\n-\n[Droga: Cisplatino](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin)\n-\n[Droga: Gemcitabina](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Gemcitabine)\n-\n[Droga: Sulfato de vincristina](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Vincristine%20Sulfate)\n-\n[Droga: Doxorrubicina](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Doxorubicin)\n-\n[Droga: Fluorouracilo](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Fluorouracil)\n-\n[Droga: Oxaliplatino](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Oxaliplatin)\n-\n[Droga: Irinotec\u00e1n](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Irinotecan)\n-\n[Droga: Sorafenib](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Sorafenib)\n-\n[Procedimiento: Resecci\u00f3n](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Resection)\n-\n[Otro: Observaci\u00f3n del paciente](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Patient%20Observation)\nDescripci\u00f3n detallada\nOBJETIVOS PRINCIPALES:\nI. Para reducir la toxicidad asociada a la terapia en pacientes con hepatoblastoma (HB) y carcinoma hepatocelular (HCC) no metast\u00e1sico sin afectar negativamente los resultados a largo plazo.\nII. Determinar la supervivencia libre de eventos (SSC) en pacientes con HB cuyo tumor se resec\u00f3 por completo en el momento del diagn\u00f3stico y no recibieron quimioterapia adyuvante (HB con histolog\u00eda fetal bien diferenciada [WDF] completamente resecada) o 2 ciclos de monoterapia con cisplatino en dosis est\u00e1ndar (completamente resecado histolog\u00eda fetal no bien diferenciada HB - 100 mg/m^2/ciclo administrados con 3 semanas de diferencia). (Grupo A) III. Demostrar que 4 a 6 ciclos de monoterapia de cisplatino en dosis bajas comprimidas a intervalos (80 mg/m^2/ciclo; 320-480 mg/m^2 en total) es adecuado para la HB de bajo riesgo. (Grupo B) IIIa. En pacientes que se resecan despu\u00e9s de 2 ciclos de monoterapia con cisplatino, comparar la SSC despu\u00e9s de una comparaci\u00f3n aleatoria de 2 versus 4 ciclos posoperatorios de monoterapia con cisplatino. (Grupo B) IIIb. En pacientes cuyos tumores se consideran irresecables despu\u00e9s de 2 ciclos de monoterapia con cisplatino, para determinar la proporci\u00f3n de tumores que se vuelven completamente resecables con 2 o 4 ciclos adicionales de quimioterapia. (Grupo B) IV. Comparar de forma aleatoria la SSC en pacientes con HB de riesgo intermedio tratados con 6 ciclos de quimioterapia con cisplatino/5-fluorouracilo/vincristina/doxorrubicina (C5VD) versus 6 ciclos de monoterapia con cisplatino comprimido a intervalos (100 mg/m^2/dosis) . (Grupo C) V. Determinar la SSC en pacientes con CHC cuyo tumor se resec\u00f3 por completo en el momento del diagn\u00f3stico que no reciben quimioterapia adyuvante (CHC completamente resecado que surge en el contexto de una enfermedad hep\u00e1tica subyacente) o 4 ciclos de cisplatino/doxorrubicina (PLADO) ( CHC completamente resecado de novo). (Grupo E) VI. Para mejorar la SSC de los pacientes con HB de alto riesgo trat\u00e1ndolos con un r\u00e9gimen de inducci\u00f3n a base de cisplatino comprimido y doxorrubicina a intervalos, seguido de una terapia de consolidaci\u00f3n adaptada a la respuesta. (Grupo D) VIa. En pacientes cuya enfermedad metast\u00e1sica se resuelve con la administraci\u00f3n de la terapia de inducci\u00f3n Societe Internationale d'Oncologie Pediatrique (SIOPEL) 4, para determinar si los prometedores resultados piloto observados en SIOPEL 4 pueden validarse en un gran estudio internacional. (Grupo D1) VIb. En pacientes cuya enfermedad metast\u00e1sica no se resuelve con la administraci\u00f3n de terapia de inducci\u00f3n con SIOPEL 4, determinar en una comparaci\u00f3n aleatoria qu\u00e9 tratamiento posterior a la inducci\u00f3n (irinotec\u00e1n y sulfato de vincristina [vincristina] alternando con carboplatino y doxorrubicina o carboplatino y etop\u00f3sido alternando con carboplatino y doxorrubicina) resultados en resultados superiores. (Grupo D Brazo CE y Brazo VI) VII. En pacientes con CHC irresecable/metast\u00e1sico en el momento del diagn\u00f3stico, determinar si la adici\u00f3n de gemcitabina y oxaliplatino (GEMOX + sorafenib) a una base de cisplatino, doxorrubicina y sorafenib mejora la respuesta a la quimioterapia, la resecabilidad y la supervivencia. (Grupo F)\nOBJETIVOS EXPLORATORIOS:\nI. Determinar si el an\u00e1lisis de estratificaci\u00f3n de riesgo de hepatoblastoma del Consorcio Internacional de tumores hep\u00e1ticos infantiles (CHIC) de grupos de muy bajo riesgo (Grupo A), bajo riesgo (Grupo B), riesgo intermedio (Grupo C) y alto riesgo (Grupo D) estratifica a los pacientes permitiendo la utilizaci\u00f3n adecuada de reg\u00edmenes de quimioterapia de intensidad variable y estrategias de resecci\u00f3n quir\u00fargica.\nII. Definir la relevancia pron\u00f3stica de un margen microsc\u00f3pico positivo en muestras de HB resecadas del Grupo A-D.\ntercero Definir la frecuencia de lesiones multifocales detectables histol\u00f3gicamente en explantes hep\u00e1ticos y espec\u00edmenes resecados en los que se detect\u00f3 enfermedad multifocal en el momento del diagn\u00f3stico y desapareci\u00f3 en las im\u00e1genes transversales despu\u00e9s del tratamiento con quimioterapia.\nIV. Definir la relevancia pron\u00f3stica en HB de un componente tumoral 'peque\u00f1o indiferenciado' y porcentaje de necrosis tumoral en espec\u00edmenes post quimioterapia.\nV. Determinar el impacto pron\u00f3stico sobre la SSC y la supervivencia general (SG) de la t\u00e9cnica de biopsia en tumores hep\u00e1ticos irresecables en el momento del diagn\u00f3stico.\nVI. Determinar la SSC y la SG a 3 a\u00f1os de los pacientes con HB que se someten a un trasplante de h\u00edgado frente a la resecci\u00f3n extrema en los pacientes de los grupos C y D.\nVIII. Determinar la SSC y la SG a 3 a\u00f1os de los pacientes del Grupo D que se someten a metastasectom\u00eda pulmonar.\nVIII. Determinar la SSC y la SG a 3 a\u00f1os de los pacientes que se someten a un trasplante de h\u00edgado por CHC.\nIX. Determinar la frecuencia de reca\u00edda en CHC no metast\u00e1sico en ni\u00f1os tratados mediante trasplante hep\u00e1tico versus resecci\u00f3n convencional.\nX. Determinar la concordancia de las pautas quir\u00fargicas basadas en la extensi\u00f3n de la enfermedad previa al tratamiento (PRETEXT) y la extensi\u00f3n de la enfermedad posterior al tratamiento (POSTTEXT) y la intervenci\u00f3n quir\u00fargica realizada.\nXI. Para recolectar muestras de tumores HB y HCC para an\u00e1lisis futuros que puedan caracterizarse molecularmente para validar biomarcadores moleculares e inmunohistoqu\u00edmicos reci\u00e9n identificados que se correlacionen con factores pron\u00f3sticos cl\u00ednicos y resultados conocidos.\nXII. Evaluar el modelo predictivo de riesgo molecular de hepatoblastoma (HB-MRP) para estratificar el riesgo de pacientes con hepatoblastoma en el contexto del ensayo AHEP1531 actual.\nXIII. Recolectar muestras para futuros an\u00e1lisis para evaluar la farmacogen\u00f3mica (PG) relacionada con la terapia con cisplatino en pacientes pedi\u00e1tricos y adolescentes con tumores hep\u00e1ticos y correlacionar la PG con la escala de clasificaci\u00f3n de Boston para la ototoxicidad.\nXIV. Recolectar para futuros an\u00e1lisis muestras tales que los nuevos biomarcadores de toxicidad renal (lipocalina asociada a gelatinasa de neutr\u00f3filos en orina [NGAL], cistatina C y Kim1) de la terapia con cisplatino puedan correlacionarse con la farmacogen\u00f3mica, otras toxicidades asociadas y los resultados.\nXV. Para determinar qu\u00e9 sistema (Children's Oncology Group [COG] PRETEXT, SIOPEL PRETEXT o una nueva definici\u00f3n h\u00edbrida de PRETEXT) de los factores de anotaci\u00f3n para V, P, E, F y R proporciona la mejor informaci\u00f3n pron\u00f3stica para determinar la respuesta a la quimioterapia, guiar terapia basada en el riesgo, predicci\u00f3n de la resecabilidad quir\u00fargica y EFS.\nXVI. Determinar la concordancia entre la evaluaci\u00f3n de la revisi\u00f3n institucional y del panel de expertos de la etapa PRETEXT y POSTTEXT en un entorno de grupo cooperativo internacional.\nCONTORNO:\nGRUPO A (HB DE MUY BAJO RIESGO): Los pacientes se asignan a 1 de 2 grupos.\nGRUPO A1 (WDF): Pacientes en observaci\u00f3n.\nGRUPO A2 (NO WDF): Los pacientes reciben cisplatino (CDDP) por v\u00eda intravenosa (IV) durante 6 horas el d\u00eda 1 despu\u00e9s de la cirug\u00eda. El tratamiento se repite cada 21 d\u00edas hasta por 2 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable.\nGRUPO B (HB DE BAJO RIESGO): Los pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1. El tratamiento se repite cada 14 d\u00edas hasta por 2 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable. Luego, los pacientes se asignan a 1 de 2 grupos.\nGRUPO B1 (RESECTABLE): Los pacientes reciben 2 ciclos de cisplatino, se someten a cirug\u00eda y luego se asignan al azar a 1 de 2 brazos (2 frente a 4 ciclos adicionales de cisplatino).\nGRUPO B1 BRAZO 4-CDDP: los pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1. El tratamiento se repite cada 14 d\u00edas hasta un total de 4 ciclos (2 antes de la cirug\u00eda, 2 despu\u00e9s de la cirug\u00eda) en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable.\nGRUPO B1 BRAZO 6-CDDP: los pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1. El tratamiento se repite cada 14 d\u00edas hasta un total de 6 ciclos (2 antes de la cirug\u00eda, 4 despu\u00e9s de la cirug\u00eda) en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable.\nGRUPO B2 (IRRESECTABLE): Los pacientes reciben 2 ciclos de cisplatino, luego se asignan a 1 de 2 brazos (resecable vs no resecable).\nGRUPO B2 BRAZO I (RESECTABLE): Los pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1. El tratamiento se repite cada 14 d\u00edas hasta un total de 6 ciclos (4 antes de la cirug\u00eda, 2 despu\u00e9s de la cirug\u00eda). Despu\u00e9s del ciclo 4, los pacientes se someten a cirug\u00eda y luego contin\u00faan con 2 ciclos adicionales de cisplatino.\nGRUPO B2 BRAZO II (IRRESECABLE): Los pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1. El tratamiento se repite cada 14 d\u00edas hasta un total de 6 ciclos.\nGRUPO C (HB DE RIESGO INTERMEDIO): Los pacientes se asignan al azar a 1 de 2 brazos.\nGRUPO C BRAZO CDDP: Los pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1. El tratamiento se repite cada 14 d\u00edas hasta por 6 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable. Los pacientes se someten a cirug\u00eda despu\u00e9s del ciclo 2 o 4.\nGRUPO C BRAZO C5VD: Los pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1, 5-fluorouracilo IV durante 1-15 minutos, sulfato de vincristina IV durante 1 minuto los d\u00edas 1, 8 y 15 y doxorrubicina IV durante 1-15 minutos los d\u00edas 1 y 2. El tratamiento se repite cada 21 d\u00edas hasta 6 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable. Los pacientes se someten a cirug\u00eda despu\u00e9s del ciclo 2 o 4.\nGRUPO D (HB DE ALTO RIESGO): SIOPEL-4 INDUCCI\u00d3N IV: Los pacientes reciben cisplatino IV durante 6 horas los d\u00edas 1, 8 y 15 (para los ciclos 1 y 2) y los d\u00edas 1 y 8 (para el ciclo 3) y doxorrubicina IV durante 1-15 minutos los d\u00edas 8 y 9 (para los ciclos 1 y 2) y los d\u00edas 1 y 2 (para el ciclo 3). Los ciclos 1 y 2 son de 28 d\u00edas; el ciclo 3 es de 21 d\u00edas. Luego, los pacientes se asignan a 1 de 2 brazos.\nGRUPO D1: TERAPIA DE CONSOLIDACI\u00d3N: Los pacientes con remisi\u00f3n pulmonar completa (ya sea con quimioterapia y/o cirug\u00eda) reciben carboplatino IV durante 1 hora el d\u00eda 1 y doxorrubicina IV durante 1-15 minutos los d\u00edas 1 y 2. El tratamiento se repite cada 21 d\u00edas durante 3 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable.\nGRUPO D2: Los pacientes con enfermedad metast\u00e1sica residual se asignan al azar a 1 de 2 brazos.\nGRUPO D2 BRAZO CE: Los pacientes reciben carboplatino IV durante 1 hora los d\u00edas 1 y 2, doxorrubicina IV durante 1-15 minutos los d\u00edas 1 y 2 durante los ciclos 1, 3 y 5, y carboplatino IV durante 1 hora y etop\u00f3sido IV durante 2 horas en el d\u00eda 1 y 2 de los ciclos 2, 4 y 6. Los tratamientos se repiten cada 21 d\u00edas durante 6 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable.\nGRUPO D2 BRAZO VI: Los pacientes reciben carboplatino IV durante 1 hora los d\u00edas 1 y 2 y doxorrubicina IV durante 1-15 minutos los d\u00edas 1 y 2 durante los ciclos 1, 3 y 5. Los pacientes tambi\u00e9n reciben sulfato de vincristina IV durante 1 minuto los d\u00edas 1 y 8 e irinotecan IV durante 60-90 minutos una vez al d\u00eda (QD) en los d\u00edas 1 a 5 de los ciclos 2, 4 y 6. Los tratamientos se repiten cada 21 d\u00edas durante 6 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable.\nGRUPO E (HCC RESECCIONADO): Los pacientes se asignan a 1 de 2 grupos.\nGRUPO E1: Los pacientes con HCC secundario a una enfermedad hep\u00e1tica subyacente solo se someten a observaci\u00f3n.\nGRUPO E2 (PLADO): Los pacientes con HCC de novo reciben cisplatino IV durante 6 horas el d\u00eda 1 y doxorrubicina IV durante 1-15 minutos los d\u00edas 1 y 2 despu\u00e9s de la cirug\u00eda. Los tratamientos se repiten cada 21 d\u00edas durante 4 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable.\nGRUPO F (CHC NO SECCIONADO Y/O METAST\u00c1SICO): Los pacientes se asignan al azar a 1 de 2 brazos.\nGROUP F ARM 1 (PLADO): Los pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1, doxorrubicina IV durante 1-15 minutos los d\u00edas 1 y 2 y sorafenib por v\u00eda oral (PO) dos veces al d\u00eda (BID) los d\u00edas 3-21. Los tratamientos se repiten cada 21 d\u00edas hasta por 3 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable. Los pacientes pueden someterse a cirug\u00eda, si los tumores son resecables, o recibir 3 ciclos adicionales del tratamiento.\nGRUPO FARMA 2 (P/GEMOX): Los pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1, doxorrubicina IV durante 1-15 minutos los d\u00edas 1 y 2 y sorafenib PO BID los d\u00edas 3-14 de los ciclos 1 y 3. Los pacientes tambi\u00e9n recibir gemcitabina IV durante 90 minutos el d\u00eda 1, oxaliplatino IV durante 2 horas el d\u00eda 1 y sorafenib VO los d\u00edas 1-14 de los ciclos 2 y 4. Los pacientes pueden someterse a cirug\u00eda, si los tumores son resecables, o recibir 4 ciclos adicionales de la tratamiento.\nDespu\u00e9s de completar el tratamiento del estudio, se realiza un seguimiento de los pacientes durante un m\u00ednimo de 2 a\u00f1os.\nTipo de estudio\nInscripci\u00f3n (Estimado)\nFase\n- Fase 2\n- Fase 3\nContactos y Ubicaciones\nUbicaciones de estudio\n-\nArabia Saudita\n-\n-\nRiyadh, Arabia Saudita, 11211\n- Suspendido\n- King Faisal Specialist Hospital and Research Centre\n-\n-\n-\nAustralia\n-\nNew South Wales\n-\nHunter Regional Mail Centre, New South Wales, Australia, 2310\n- Reclutamiento\n- John Hunter Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: (02) 4985 5180\n-\nInvestigador principal:\n- Elizabeth L. Hesketh\n-\nRandwick, New South Wales, Australia, 2031\n- Reclutamiento\n- Sydney Children's Hospital\n-\nInvestigador principal:\n- Draga Barbaric\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: (02) 9382-1721\n-\nWestmead, New South Wales, Australia, 2145\n- Reclutamiento\n- The Children's Hospital at Westmead\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 61-2-9845 1400\n-\nInvestigador principal:\n- Bhavna Padhye\n-\n-\nQueensland\n-\nSouth Brisbane, Queensland, Australia, 4101\n- Reclutamiento\n- Queensland Children's Hospital\n-\nInvestigador principal:\n- Draga Barbaric\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 61 7 3068 1111\n-\n-\nSouth Australia\n-\nNorth Adelaide, South Australia, Australia, 5006\n- Activo, no reclutando\n- Women's and Children's Hospital-Adelaide\n-\n-\nVictoria\n-\nParkville, Victoria, Australia, 3052\n- Reclutamiento\n- Royal Children's Hospital\n-\nInvestigador principal:\n- Michael J. Sullivan\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 61 3 9345 5656\n- Correo electr\u00f3nico:\n[Jordan.Hansford@rch.org.au](mailto:Jordan.Hansford@rch.org.au?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\n-\nWestern Australia\n-\nPerth, Western Australia, Australia, 6009\n- Reclutamiento\n- Perth Children's Hospital\n-\n-\nInvestigador principal:\n- Marianne B. Phillips\n-\n-\n-\nCanad\u00e1\n-\n-\nQuebec, Canad\u00e1, G1V 4G2\n- Reclutamiento\n- Centre Hospitalier Universitaire de Quebec\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 418-525-4444\n-\nInvestigador principal:\n- Bruno Michon\n-\n-\nAlberta\n-\nCalgary, Alberta, Canad\u00e1, T3B 6A8\n- Reclutamiento\n- Alberta Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 403-220-6898\n- Correo electr\u00f3nico:\n[research4kids@ucalgary.ca](mailto:research4kids@ucalgary.ca?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Victor A. Lewis\n-\nEdmonton, Alberta, Canad\u00e1, T6G 2B7\n- Reclutamiento\n- University of Alberta Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 780-407-8798\n- Correo electr\u00f3nico:\n[pedsoncologyresearch@ahs.ca](mailto:pedsoncologyresearch@ahs.ca?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Sarah J. McKillop\n-\n-\nManitoba\n-\nWinnipeg, Manitoba, Canad\u00e1, R3E 0V9\n- Reclutamiento\n- CancerCare Manitoba\n-\nInvestigador principal:\n- Issai M. Vanan\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 866-561-1026\n- Correo electr\u00f3nico:\n[ctu_web@cancercare.mb.ca](mailto:ctu_web@cancercare.mb.ca?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\n-\nNova Scotia\n-\nHalifax, Nova Scotia, Canad\u00e1, B3K 6R8\n- Reclutamiento\n- IWK Health Centre\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 902-470-8520\n- Correo electr\u00f3nico:\n[Research@iwk.nshealth.ca](mailto:Research@iwk.nshealth.ca?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Craig Erker\n-\n-\nOntario\n-\nHamilton, Ontario, Canad\u00e1, L8N 3Z5\n- Reclutamiento\n- McMaster Children's Hospital at Hamilton Health Sciences\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 905-521-2100\n-\nInvestigador principal:\n- Uma H. Athale\n-\nKingston, Ontario, Canad\u00e1, K7L 2V7\n- Reclutamiento\n- Kingston Health Sciences Centre\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 613-549-6666\n- Correo electr\u00f3nico:\n[cc-clinicaltrials@kgh.kari.net](mailto:cc-clinicaltrials@kgh.kari.net?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Laura Wheaton\n-\nLondon, Ontario, Canad\u00e1, N6A 5W9\n- Reclutamiento\n- Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 519-685-8306\n-\nInvestigador principal:\n- Shayna M. Zelcer\n-\nToronto, Ontario, Canad\u00e1, M5G 1X8\n- Reclutamiento\n- Hospital for Sick Children\n-\nInvestigador principal:\n- Furqan Shaikh\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 416-813-7654\n- Correo electr\u00f3nico:\n[ask.CRS@sickkids.ca](mailto:ask.CRS@sickkids.ca?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\n-\nQuebec\n-\nMontreal, Quebec, Canad\u00e1, H3H 1P3\n- Reclutamiento\n- The Montreal Children's Hospital of the MUHC\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 514-412-4445\n- Correo electr\u00f3nico:\n[info@thechildren.com](mailto:info@thechildren.com?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Sharon B. Abish\n-\nMontreal, Quebec, Canad\u00e1, H3T 1C5\n- Reclutamiento\n- Centre Hospitalier Universitaire Sainte-Justine\n-\nInvestigador principal:\n- Monia Marzouki\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 514-345-4931\n- Correo electr\u00f3nico:\n[yvan.samson@umontreal.ca](mailto:yvan.samson@umontreal.ca?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\n-\nSaskatchewan\n-\nSaskatoon, Saskatchewan, Canad\u00e1, S7N 0W8\n- Reclutamiento\n- Jim Pattison Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 306-766-5573\n-\nInvestigador principal:\n- Kathleen Felton\n-\nSaskatoon, Saskatchewan, Canad\u00e1, S7N 4H4\n- Suspendido\n- Saskatoon Cancer Centre\n-\n-\n-\nEstados Unidos\n-\nAlabama\n-\nBirmingham, Alabama, Estados Unidos, 35233\n- Reclutamiento\n- Children's Hospital of Alabama\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 205-638-9285\n- Correo electr\u00f3nico:\n[oncologyresearch@peds.uab.edu](mailto:oncologyresearch@peds.uab.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Jamie M. Aye\n-\n-\nAlaska\n-\nAnchorage, Alaska, Estados Unidos, 99508\n- Reclutamiento\n- Providence Alaska Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 907-212-6871\n- Correo electr\u00f3nico:\n[AKPAMC.OncologyResearchSupport@providence.org](mailto:AKPAMC.OncologyResearchSupport@providence.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Brenda J. Wittman\n-\n-\nArizona\n-\nMesa, Arizona, Estados Unidos, 85202\n- Reclutamiento\n- Banner Children's at Desert\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 480-412-3100\n-\nInvestigador principal:\n- Joseph C. Torkildson\n-\nPhoenix, Arizona, Estados Unidos, 85016\n- Reclutamiento\n- Phoenix Childrens Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 602-546-0920\n-\nInvestigador principal:\n- Alok K. Kothari\n-\n-\nArkansas\n-\nLittle Rock, Arkansas, Estados Unidos, 72202-3591\n- Reclutamiento\n- Arkansas Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 501-364-7373\n-\nInvestigador principal:\n- David L. Becton\n-\n-\nCalifornia\n-\nDowney, California, Estados Unidos, 90242\n- Reclutamiento\n- Kaiser Permanente Downey Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 626-564-3455\n-\nInvestigador principal:\n- Robert M. Cooper\n-\nLoma Linda, California, Estados Unidos, 92354\n- Reclutamiento\n- Loma Linda University Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 909-558-4050\n-\nInvestigador principal:\n- Albert Kheradpour\n-\nLong Beach, California, Estados Unidos, 90806\n- Reclutamiento\n- Miller Children's and Women's Hospital Long Beach\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 562-933-5600\n-\nInvestigador principal:\n- Jacqueline N. Casillas\n-\nLos Angeles, California, Estados Unidos, 90027\n- Reclutamiento\n- Children's Hospital Los Angeles\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 323-361-4110\n-\nInvestigador principal:\n- Leo Mascarenhas\n-\nLos Angeles, California, Estados Unidos, 90095\n- Reclutamiento\n- Mattel Children's Hospital UCLA\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 310-825-6708\n-\nInvestigador principal:\n- Noah C. Federman\n-\nMadera, California, Estados Unidos, 93636\n- Reclutamiento\n- Valley Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 559-353-3000\n- Correo electr\u00f3nico:\n[Research@valleychildrens.org](mailto:Research@valleychildrens.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Karen S. Fernandez\n-\nOakland, California, Estados Unidos, 94611\n- Reclutamiento\n- Kaiser Permanente-Oakland\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 877-642-4691\n- Correo electr\u00f3nico:\n[Kpoct@kp.org](mailto:Kpoct@kp.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Aarati V. Rao\n-\nOakland, California, Estados Unidos, 94609\n- Reclutamiento\n- UCSF Benioff Children's Hospital Oakland\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 510-428-3324\n- Correo electr\u00f3nico:\n[Carla.Golden@ucsf.edu](mailto:Carla.Golden@ucsf.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Carla B. Golden\n-\nOrange, California, Estados Unidos, 92868\n- Reclutamiento\n- Children's Hospital of Orange County\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 714-509-8646\n- Correo electr\u00f3nico:\n[oncresearch@choc.org](mailto:oncresearch@choc.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Elyssa M. Rubin\n-\nPalo Alto, California, Estados Unidos, 94304\n- Reclutamiento\n- Lucile Packard Children's Hospital Stanford University\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 800-694-0012\n- Correo electr\u00f3nico:\n[ccto-office@stanford.edu](mailto:ccto-office@stanford.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Jay Michael S. Balagtas\n-\nSacramento, California, Estados Unidos, 95817\n- Reclutamiento\n- University of California Davis Comprehensive Cancer Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 916-734-3089\n-\nInvestigador principal:\n- Marcio H. Malogolowkin\n-\nSacramento, California, Estados Unidos, 95816\n- Reclutamiento\n- Sutter Medical Center Sacramento\n-\nContacto:\n- Site Public Contact\n- Correo electr\u00f3nico:\n[Melanie.Cook@sutterhealth.org](mailto:Melanie.Cook@sutterhealth.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Yung S. Yim\n-\nSan Diego, California, Estados Unidos, 92123\n- Reclutamiento\n- Rady Children's Hospital - San Diego\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 858-966-5934\n-\nInvestigador principal:\n- William D. Roberts\n-\nSan Diego, California, Estados Unidos, 92134\n- Reclutamiento\n- Naval Medical Center -San Diego\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 619-532-8712\n-\nInvestigador principal:\n- Yoko T. Udaka\n-\nSan Francisco, California, Estados Unidos, 94158\n- Reclutamiento\n- UCSF Medical Center-Mission Bay\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 877-827-3222\n- Correo electr\u00f3nico:\n[cancertrials@ucsf.edu](mailto:cancertrials@ucsf.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Arun A. Rangaswami\n-\nTorrance, California, Estados Unidos, 90502\n- Activo, no reclutando\n- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center\n-\n-\nColorado\n-\nAurora, Colorado, Estados Unidos, 80045\n- Reclutamiento\n- Children's Hospital Colorado\n-\nInvestigador principal:\n- Emily Blauel\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 303-764-5056\n- Correo electr\u00f3nico:\n[josh.b.gordon@nsmtp.kp.org](mailto:josh.b.gordon@nsmtp.kp.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nDenver, Colorado, Estados Unidos, 80218\n- Reclutamiento\n- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 303-839-6000\n-\nInvestigador principal:\n- Jennifer J. Clark\n-\n-\nConnecticut\n-\nHartford, Connecticut, Estados Unidos, 06106\n- Reclutamiento\n- Connecticut Children's Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 860-545-9981\n-\nInvestigador principal:\n- Michael S. Isakoff\n-\nNew Haven, Connecticut, Estados Unidos, 06520\n- Reclutamiento\n- Yale University\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 203-785-5702\n- Correo electr\u00f3nico:\n[canceranswers@yale.edu](mailto:canceranswers@yale.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Farzana Pashankar\n-\n-\nDelaware\n-\nWilmington, Delaware, Estados Unidos, 19803\n- Reclutamiento\n- Alfred I duPont Hospital for Children\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 302-651-5572\n- Correo electr\u00f3nico:\n[Allison.bruce@nemours.org](mailto:Allison.bruce@nemours.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Ramamoorthy Nagasubramanian\n-\n-\nDistrict of Columbia\n-\nWashington, District of Columbia, Estados Unidos, 20010\n- Reclutamiento\n- Children's National Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 202-884-2549\n-\nInvestigador principal:\n- Jeffrey S. Dome\n-\nWashington, District of Columbia, Estados Unidos, 20007\n- Reclutamiento\n- MedStar Georgetown University Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 202-444-2223\n-\nInvestigador principal:\n- Nina S. Kadan-Lottick\n-\n-\nFlorida\n-\nFort Myers, Florida, Estados Unidos, 33908\n- Reclutamiento\n- Golisano Children's Hospital of Southwest Florida\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 239-343-5333\n- Correo electr\u00f3nico:\n[molly.arnstrom@leehealth.org](mailto:molly.arnstrom@leehealth.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Emad K. Salman\n-\nGainesville, Florida, Estados Unidos, 32610\n- Reclutamiento\n- University of Florida Health Science Center - Gainesville\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 352-273-8010\n- Correo electr\u00f3nico:\n[cancer-center@ufl.edu](mailto:cancer-center@ufl.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- William B. Slayton\n-\nHollywood, Florida, Estados Unidos, 33021\n- Reclutamiento\n- Memorial Regional Hospital/Joe DiMaggio Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 954-265-1847\n- Correo electr\u00f3nico:\n[OHR@mhs.net](mailto:OHR@mhs.net?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Iftikhar Hanif\n-\nJacksonville, Florida, Estados Unidos, 32207\n- Reclutamiento\n- Nemours Children's Clinic-Jacksonville\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 302-651-5572\n- Correo electr\u00f3nico:\n[Allison.bruce@nemours.org](mailto:Allison.bruce@nemours.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Ramamoorthy Nagasubramanian\n-\nMiami, Florida, Estados Unidos, 33155\n- Reclutamiento\n- Nicklaus Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 888-624-2778\n-\nInvestigador principal:\n- Ziad A. Khatib\n-\nMiami, Florida, Estados Unidos, 33136\n- Reclutamiento\n- University of Miami Miller School of Medicine-Sylvester Cancer Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 305-243-2647\n-\nInvestigador principal:\n- Julio C. Barredo\n-\nOrlando, Florida, Estados Unidos, 32806\n- Reclutamiento\n- Arnold Palmer Hospital For Children\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 321-841-5357\n- Correo electr\u00f3nico:\n[Jennifer.spinelli@orlandohealth.com](mailto:Jennifer.spinelli@orlandohealth.com?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Amy A. Smith\n-\nOrlando, Florida, Estados Unidos, 32827\n- Reclutamiento\n- Nemours Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 302-651-5572\n- Correo electr\u00f3nico:\n[Allison.bruce@nemours.org](mailto:Allison.bruce@nemours.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Ramamoorthy Nagasubramanian\n-\nOrlando, Florida, Estados Unidos, 32803\n- Reclutamiento\n- AdventHealth Orlando\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 407-303-2090\n- Correo electr\u00f3nico:\n[FH.Cancer.Research@flhosp.org](mailto:FH.Cancer.Research@flhosp.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Fouad M. Hajjar\n-\nPensacola, Florida, Estados Unidos, 32504\n- Reclutamiento\n- Sacred Heart Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 850-416-4611\n- Correo electr\u00f3nico:\n[eebrou@ascension.org](mailto:eebrou@ascension.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Erlyn C. Smith\n-\nSaint Petersburg, Florida, Estados Unidos, 33701\n- Reclutamiento\n- Johns Hopkins All Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 727-767-4784\n- Correo electr\u00f3nico:\n[Ashley.Repp@jhmi.edu](mailto:Ashley.Repp@jhmi.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Jonathan L. Metts\n-\nTampa, Florida, Estados Unidos, 33606\n- Reclutamiento\n- Tampa General Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 813-844-7829\n- Correo electr\u00f3nico:\n[syapchanyk@tgh.org](mailto:syapchanyk@tgh.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Andrew J. Galligan\n-\nTampa, Florida, Estados Unidos, 33607\n- Reclutamiento\n- Saint Joseph's Hospital/Children's Hospital-Tampa\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 813-357-0849\n- Correo electr\u00f3nico:\n[jennifer.manns@baycare.org](mailto:jennifer.manns@baycare.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Don E. Eslin\n-\nWest Palm Beach, Florida, Estados Unidos, 33407\n- Reclutamiento\n- Saint Mary's Hospital\n-\nInvestigador principal:\n- Muaz A. Alrazzak\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 561-881-2815\n-\n-\nGeorgia\n-\nAtlanta, Georgia, Estados Unidos, 30322\n- Reclutamiento\n- Children's Healthcare of Atlanta - Egleston\n-\nInvestigador principal:\n- Kathryn S. Sutton\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 404-785-2025\n- Correo electr\u00f3nico:\n[Leann.Schilling@choa.org](mailto:Leann.Schilling@choa.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nAugusta, Georgia, Estados Unidos, 30912\n- Reclutamiento\n- Augusta University Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 706-721-2388\n- Correo electr\u00f3nico:\n[ga_cares@augusta.edu](mailto:ga_cares@augusta.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Colleen H. McDonough\n-\nSavannah, Georgia, Estados Unidos, 31404\n- Reclutamiento\n- Memorial Health University Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 912-350-7887\n- Correo electr\u00f3nico:\n[Lorraine.OHara@hcahealthcare.com](mailto:Lorraine.OHara@hcahealthcare.com?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Andrew L. Pendleton\n-\n-\nHawaii\n-\nHonolulu, Hawaii, Estados Unidos, 96826\n- Reclutamiento\n- Kapiolani Medical Center for Women and Children\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 808-983-6090\n-\nInvestigador principal:\n- Wade T. Kyono\n-\n-\nIdaho\n-\nBoise, Idaho, Estados Unidos, 83712\n- Reclutamiento\n- Saint Luke's Cancer Institute - Boise\n-\nInvestigador principal:\n- Martha M. Pacheco\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 208-381-2774\n- Correo electr\u00f3nico:\n[eslinget@slhs.org](mailto:eslinget@slhs.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\n-\nIllinois\n-\nChicago, Illinois, Estados Unidos, 60611\n- Reclutamiento\n- Lurie Children's Hospital-Chicago\n-\nInvestigador principal:\n- Amy L. Walz\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 773-880-4562\n-\nChicago, Illinois, Estados Unidos, 60637\n- Reclutamiento\n- University of Chicago Comprehensive Cancer Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 773-702-8222\n- Correo electr\u00f3nico:\n[cancerclinicaltrials@bsd.uchicago.edu](mailto:cancerclinicaltrials@bsd.uchicago.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Ami V. Desai\n-\nChicago, Illinois, Estados Unidos, 60612\n- Reclutamiento\n- University of Illinois\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 312-355-3046\n-\nInvestigador principal:\n- Mary L. Schmidt\n-\nMaywood, Illinois, Estados Unidos, 60153\n- Reclutamiento\n- Loyola University Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 708-226-4357\n-\nInvestigador principal:\n- Eugene Suh\n-\nOak Lawn, Illinois, Estados Unidos, 60453\n- Reclutamiento\n- Advocate Children's Hospital-Oak Lawn\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 847-723-7570\n-\nInvestigador principal:\n- Rebecca E. McFall\n-\nPark Ridge, Illinois, Estados Unidos, 60068\n- Reclutamiento\n- Advocate Children's Hospital-Park Ridge\n-\n-\nInvestigador principal:\n- Rebecca E. McFall\n-\nPeoria, Illinois, Estados Unidos, 61637\n- Reclutamiento\n- Saint Jude Midwest Affiliate\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 888-226-4343\n-\nInvestigador principal:\n- Prerna Kumar\n-\nSpringfield, Illinois, Estados Unidos, 62702\n- Reclutamiento\n- Southern Illinois University School of Medicine\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 217-545-7929\n-\nInvestigador principal:\n- Gregory P. Brandt\n-\n-\nIndiana\n-\nIndianapolis, Indiana, Estados Unidos, 46202\n- Reclutamiento\n- Riley Hospital for Children\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 800-248-1199\n-\nInvestigador principal:\n- Sandeep Batra\n-\nIndianapolis, Indiana, Estados Unidos, 46260\n- Reclutamiento\n- Ascension Saint Vincent Indianapolis Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 317-338-2194\n- Correo electr\u00f3nico:\n[research@stvincent.org](mailto:research@stvincent.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Bassem I. Razzouk\n-\n-\nIowa\n-\nDes Moines, Iowa, Estados Unidos, 50309\n- Reclutamiento\n- Blank Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 515-241-8912\n- Correo electr\u00f3nico:\n[samantha.mallory@unitypoint.org](mailto:samantha.mallory@unitypoint.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Samantha L. Mallory\n-\nIowa City, Iowa, Estados Unidos, 52242\n- Reclutamiento\n- University of Iowa/Holden Comprehensive Cancer Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 800-237-1225\n-\nInvestigador principal:\n- David S. Dickens\n-\n-\nKentucky\n-\nLexington, Kentucky, Estados Unidos, 40536\n- Reclutamiento\n- University of Kentucky/Markey Cancer Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 859-257-3379\n-\nInvestigador principal:\n- James T. Badgett\n-\nLouisville, Kentucky, Estados Unidos, 40202\n- Reclutamiento\n- Norton Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 502-629-5500\n- Correo electr\u00f3nico:\n[CancerResource@nortonhealthcare.org](mailto:CancerResource@nortonhealthcare.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Ashok B. Raj\n-\n-\nLouisiana\n-\nNew Orleans, Louisiana, Estados Unidos, 70118\n- Reclutamiento\n- Children's Hospital New Orleans\n-\nContacto:\n- Site Public Contact\n- Correo electr\u00f3nico:\n[CHResearch@lcmchealth.org](mailto:CHResearch@lcmchealth.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Lolie C. Yu\n-\nNew Orleans, Louisiana, Estados Unidos, 70121\n- Reclutamiento\n- Ochsner Medical Center Jefferson\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 504-842-8084\n- Correo electr\u00f3nico:\n[Elisemarie.curry@ochsner.org](mailto:Elisemarie.curry@ochsner.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Craig Lotterman\n-\n-\nMaine\n-\nBangor, Maine, Estados Unidos, 04401\n- Suspendido\n- Eastern Maine Medical Center\n-\nScarborough, Maine, Estados Unidos, 04074\n- Reclutamiento\n- Maine Children's Cancer Program\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 207-396-7581\n- Correo electr\u00f3nico:\n[sverwys@mmc.org](mailto:sverwys@mmc.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Eric C. Larsen\n-\n-\nMaryland\n-\nBaltimore, Maryland, Estados Unidos, 21287\n- Reclutamiento\n- Johns Hopkins University/Sidney Kimmel Cancer Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 410-955-8804\n- Correo electr\u00f3nico:\n[jhcccro@jhmi.edu](mailto:jhcccro@jhmi.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Alan D. Friedman\n-\nBaltimore, Maryland, Estados Unidos, 21215\n- Reclutamiento\n- Sinai Hospital of Baltimore\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 410-601-6120\n- Correo electr\u00f3nico:\n[pridgely@lifebridgehealth.org](mailto:pridgely@lifebridgehealth.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Jason M. Fixler\n-\nBaltimore, Maryland, Estados Unidos, 21201\n- Reclutamiento\n- University of Maryland/Greenebaum Cancer Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 800-888-8823\n-\nInvestigador principal:\n- Teresa A. York\n-\nBethesda, Maryland, Estados Unidos, 20889-5600\n- Reclutamiento\n- Walter Reed National Military Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 301-319-2100\n-\nInvestigador principal:\n- Allen I. Stering\n-\n-\nMassachusetts\n-\nBoston, Massachusetts, Estados Unidos, 02114\n- Reclutamiento\n- Massachusetts General Hospital Cancer Center\n-\nInvestigador principal:\n- Allison F. O'Neill\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 877-726-5130\n-\nBoston, Massachusetts, Estados Unidos, 02215\n- Reclutamiento\n- Dana-Farber Cancer Institute\n-\nInvestigador principal:\n- Allison F. O'Neill\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 877-442-3324\n-\nBoston, Massachusetts, Estados Unidos, 02111\n- Activo, no reclutando\n- Tufts Children's Hospital\n-\nSpringfield, Massachusetts, Estados Unidos, 01199\n- Reclutamiento\n- Baystate Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 413-794-3565\n- Correo electr\u00f3nico:\n[tamara.wrenn@baystatehealth.org](mailto:tamara.wrenn@baystatehealth.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Joanna G. Luty\n-\n-\nMichigan\n-\nAnn Arbor, Michigan, Estados Unidos, 48109\n- Reclutamiento\n- C S Mott Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 800-865-1125\n-\nInvestigador principal:\n- Laura Sedig\n-\nDetroit, Michigan, Estados Unidos, 48201\n- Activo, no reclutando\n- Wayne State University/Karmanos Cancer Institute\n-\nDetroit, Michigan, Estados Unidos, 48201\n- Reclutamiento\n- Children's Hospital of Michigan\n-\nInvestigador principal:\n- Alissa M. Martin\n-\n-\nDetroit, Michigan, Estados Unidos, 48236\n- Activo, no reclutando\n- Ascension Saint John Hospital\n-\nEast Lansing, Michigan, Estados Unidos, 48824-7016\n- Reclutamiento\n- Michigan State University Clinical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 517-975-9547\n-\nInvestigador principal:\n- Laura E. Agresta\n-\nGrand Rapids, Michigan, Estados Unidos, 49503\n- Reclutamiento\n- Helen DeVos Children's Hospital at Spectrum Health\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 616-391-1230\n- Correo electr\u00f3nico:\n[crcwm-regulatory@crcwm.org](mailto:crcwm-regulatory@crcwm.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Kathleen J. Yost\n-\nGrand Rapids, Michigan, Estados Unidos, 49503\n- Suspendido\n- Spectrum Health at Butterworth Campus\n-\nKalamazoo, Michigan, Estados Unidos, 49007\n- Reclutamiento\n- Bronson Methodist Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 616-391-1230\n- Correo electr\u00f3nico:\n[crcwm-regulatory@crcwm.org](mailto:crcwm-regulatory@crcwm.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Kathleen J. Yost\n-\nKalamazoo, Michigan, Estados Unidos, 49007\n- Suspendido\n- West Michigan Cancer Center\n-\nRoyal Oak, Michigan, Estados Unidos, 48073\n- Reclutamiento\n- Beaumont Children's Hospital-Royal Oak\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 248-551-7695\n-\nInvestigador principal:\n- Laura K. Gowans\n-\n-\nMinnesota\n-\nMinneapolis, Minnesota, Estados Unidos, 55404\n- Reclutamiento\n- Children's Hospitals and Clinics of Minnesota - Minneapolis\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 612-813-5193\n-\nInvestigador principal:\n- Michael K. Richards\n-\nMinneapolis, Minnesota, Estados Unidos, 55455\n- Reclutamiento\n- University of Minnesota/Masonic Cancer Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 612-624-2620\n-\nInvestigador principal:\n- Emily G. Greengard\n-\nRochester, Minnesota, Estados Unidos, 55905\n- Reclutamiento\n- Mayo Clinic in Rochester\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 855-776-0015\n-\nInvestigador principal:\n- Wendy Allen-Rhoades\n-\n-\nMississippi\n-\nJackson, Mississippi, Estados Unidos, 39216\n- Reclutamiento\n- University of Mississippi Medical Center\n-\nInvestigador principal:\n- Betty L. Herrington\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 601-815-6700\n-\n-\nMissouri\n-\nColumbia, Missouri, Estados Unidos, 65201\n- Reclutamiento\n- Columbia Regional\n-\n-\nInvestigador principal:\n- Barbara A. Gruner\n-\nKansas City, Missouri, Estados Unidos, 64108\n- Reclutamiento\n- Children's Mercy Hospitals and Clinics\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 816-302-6808\n- Correo electr\u00f3nico:\n[rryan@cmh.edu](mailto:rryan@cmh.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Keith J. August\n-\nSaint Louis, Missouri, Estados Unidos, 63110\n- Reclutamiento\n- Washington University School of Medicine\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 800-600-3606\n- Correo electr\u00f3nico:\n[info@siteman.wustl.edu](mailto:info@siteman.wustl.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Frederick S. Huang\n-\nSaint Louis, Missouri, Estados Unidos, 63104\n- Reclutamiento\n- Cardinal Glennon Children's Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 314-268-4000\n-\nInvestigador principal:\n- William S. Ferguson\n-\nSaint Louis, Missouri, Estados Unidos, 63141\n- Reclutamiento\n- Mercy Hospital Saint Louis\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 314-251-7066\n-\nInvestigador principal:\n- Robin D. Hanson\n-\n-\nNebraska\n-\nOmaha, Nebraska, Estados Unidos, 68114\n- Reclutamiento\n- Children's Hospital and Medical Center of Omaha\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 402-955-3949\n-\nInvestigador principal:\n- Jill C. Beck\n-\nOmaha, Nebraska, Estados Unidos, 68198\n- Reclutamiento\n- University of Nebraska Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 402-559-6941\n- Correo electr\u00f3nico:\n[unmcrsa@unmc.edu](mailto:unmcrsa@unmc.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Jill C. Beck\n-\n-\nNevada\n-\nLas Vegas, Nevada, Estados Unidos, 89102\n- Reclutamiento\n- University Medical Center of Southern Nevada\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 702-384-0013\n- Correo electr\u00f3nico:\n[research@sncrf.org](mailto:research@sncrf.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Alan K. Ikeda\n-\nLas Vegas, Nevada, Estados Unidos, 89109\n- Reclutamiento\n- Sunrise Hospital and Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 702-384-0013\n- Correo electr\u00f3nico:\n[research@sncrf.org](mailto:research@sncrf.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Alan K. Ikeda\n-\nLas Vegas, Nevada, Estados Unidos, 89135\n- Reclutamiento\n- Alliance for Childhood Diseases/Cure 4 the Kids Foundation\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 702-384-0013\n- Correo electr\u00f3nico:\n[research@sncrf.org](mailto:research@sncrf.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Alan K. Ikeda\n-\nLas Vegas, Nevada, Estados Unidos, 89144\n- Reclutamiento\n- Summerlin Hospital Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 702-384-0013\n- Correo electr\u00f3nico:\n[research@sncrf.org](mailto:research@sncrf.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Alan K. Ikeda\n-\nReno, Nevada, Estados Unidos, 89502\n- Reclutamiento\n- Renown Regional Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 702-384-0013\n- Correo electr\u00f3nico:\n[research@sncrf.org](mailto:research@sncrf.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Alan K. Ikeda\n-\n-\nNew Hampshire\n-\nLebanon, New Hampshire, Estados Unidos, 03756\n- Reclutamiento\n- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center\n-\nInvestigador principal:\n- Angela Ricci\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 800-639-6918\n- Correo electr\u00f3nico:\n[cancer.research.nurse@dartmouth.edu](mailto:cancer.research.nurse@dartmouth.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\n-\nNew Jersey\n-\nHackensack, New Jersey, Estados Unidos, 07601\n- Reclutamiento\n- Hackensack University Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 201-996-2879\n-\nInvestigador principal:\n- Katharine Offer\n-\nMorristown, New Jersey, Estados Unidos, 07960\n- Reclutamiento\n- Morristown Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 973-971-5900\n-\nInvestigador principal:\n- Kathryn L. Laurie\n-\nNew Brunswick, New Jersey, Estados Unidos, 08903\n- Reclutamiento\n- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital\n-\nInvestigador principal:\n- Scott Moerdler\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 732-235-8675\n-\nNewark, New Jersey, Estados Unidos, 07112\n- Reclutamiento\n- Newark Beth Israel Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 973-926-7230\n- Correo electr\u00f3nico:\n[Christine.Kosmides@rwjbh.org](mailto:Christine.Kosmides@rwjbh.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Teena Bhatla\n-\nPaterson, New Jersey, Estados Unidos, 07503\n- Reclutamiento\n- Saint Joseph's Regional Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 973-754-2207\n- Correo electr\u00f3nico:\n[HallL@sjhmc.org](mailto:HallL@sjhmc.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Alissa Kahn\n-\n-\nNew Mexico\n-\nAlbuquerque, New Mexico, Estados Unidos, 87102\n- Reclutamiento\n- University of New Mexico Cancer Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 505-925-0348\n- Correo electr\u00f3nico:\n[HSC-ClinicalTrialInfo@salud.unm.edu](mailto:HSC-ClinicalTrialInfo@salud.unm.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Jessica M. Valdez\n-\n-\nNew York\n-\nAlbany, New York, Estados Unidos, 12208\n- Reclutamiento\n- Albany Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 518-262-5513\n-\nInvestigador principal:\n- Lauren R. Weintraub\n-\nBronx, New York, Estados Unidos, 10467\n- Reclutamiento\n- Montefiore Medical Center - Moses Campus\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 718-379-6866\n- Correo electr\u00f3nico:\n[eskwak@montefiore.org](mailto:eskwak@montefiore.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Lisa Gennarini\n-\nBuffalo, New York, Estados Unidos, 14263\n- Reclutamiento\n- Roswell Park Cancer Institute\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 800-767-9355\n- Correo electr\u00f3nico:\n[askroswell@roswellpark.org](mailto:askroswell@roswellpark.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Clare J. Twist\n-\nNew Hyde Park, New York, Estados Unidos, 11040\n- Reclutamiento\n- The Steven and Alexandra Cohen Children's Medical Center of New York\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 718-470-3460\n-\nInvestigador principal:\n- Carolyn F. Levy\n-\nNew York, New York, Estados Unidos, 10032\n- Reclutamiento\n- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 212-305-6361\n- Correo electr\u00f3nico:\n[nr2616@cumc.columbia.edu](mailto:nr2616@cumc.columbia.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Nobuko Hijiya\n-\nNew York, New York, Estados Unidos, 10065\n- Reclutamiento\n- Memorial Sloan Kettering Cancer Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 212-639-7592\n-\nInvestigador principal:\n- Michael V. Ortiz\n-\nNew York, New York, Estados Unidos, 10016\n- Reclutamiento\n- Laura and Isaac Perlmutter Cancer Center at NYU Langone\n-\nContacto:\n- Site Public Contact\n- Correo electr\u00f3nico:\n[CancerTrials@nyulangone.org](mailto:CancerTrials@nyulangone.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Sharon L. Gardner\n-\nNew York, New York, Estados Unidos, 10029\n- Reclutamiento\n- Mount Sinai Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 212-824-7309\n- Correo electr\u00f3nico:\n[CCTO@mssm.edu](mailto:CCTO@mssm.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Gary D. Crouch\n-\nNew York, New York, Estados Unidos, 10065\n- Reclutamiento\n- NYP/Weill Cornell Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 212-746-1848\n-\nInvestigador principal:\n- Alexander J. Chou\n-\nStony Brook, New York, Estados Unidos, 11794\n- Reclutamiento\n- Stony Brook University Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 800-862-2215\n-\nInvestigador principal:\n- Laura E. Hogan\n-\nSyracuse, New York, Estados Unidos, 13210\n- Reclutamiento\n- State University of New York Upstate Medical University\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 315-464-5476\n-\nInvestigador principal:\n- Philip M. Monteleone\n-\nValhalla, New York, Estados Unidos, 10595\n- Reclutamiento\n- New York Medical College\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 914-594-3794\n-\nInvestigador principal:\n- Jessica C. Hochberg\n-\n-\nNorth Carolina\n-\nAsheville, North Carolina, Estados Unidos, 28801\n- Reclutamiento\n- Mission Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 828-213-7055\n- Correo electr\u00f3nico:\n[NCDV.ResearchRegulatory@HCAHealthcare.com](mailto:NCDV.ResearchRegulatory@HCAHealthcare.com?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Douglas J. Scothorn\n-\nChapel Hill, North Carolina, Estados Unidos, 27599\n- Reclutamiento\n- UNC Lineberger Comprehensive Cancer Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 877-668-0683\n- Correo electr\u00f3nico:\n[cancerclinicaltrials@med.unc.edu](mailto:cancerclinicaltrials@med.unc.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Stuart H. Gold\n-\nCharlotte, North Carolina, Estados Unidos, 28203\n- Reclutamiento\n- Carolinas Medical Center/Levine Cancer Institute\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 800-804-9376\n-\nInvestigador principal:\n- Joel A. Kaplan\n-\nCharlotte, North Carolina, Estados Unidos, 28204\n- Reclutamiento\n- Novant Health Presbyterian Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 980-201-6360\n- Correo electr\u00f3nico:\n[kashah@novanthealth.org](mailto:kashah@novanthealth.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Jessica A. Bell\n-\nDurham, North Carolina, Estados Unidos, 27710\n- Reclutamiento\n- Duke University Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 888-275-3853\n-\nInvestigador principal:\n- Lars M. Wagner\n-\nWinston-Salem, North Carolina, Estados Unidos, 27157\n- Reclutamiento\n- Wake Forest University Health Sciences\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 336-713-6771\n-\nInvestigador principal:\n- Thomas W. McLean\n-\n-\nOhio\n-\nAkron, Ohio, Estados Unidos, 44308\n- Reclutamiento\n- Children's Hospital Medical Center of Akron\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 330-543-3193\n-\nInvestigador principal:\n- Erin Wright\n-\nCincinnati, Ohio, Estados Unidos, 45229\n- Reclutamiento\n- Cincinnati Children's Hospital Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 513-636-2799\n- Correo electr\u00f3nico:\n[cancer@cchmc.org](mailto:cancer@cchmc.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- James I. Geller\n-\nCleveland, Ohio, Estados Unidos, 44195\n- Reclutamiento\n- Cleveland Clinic Foundation\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 866-223-8100\n- Correo electr\u00f3nico:\n[TaussigResearch@ccf.org](mailto:TaussigResearch@ccf.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Rabi Hanna\n-\nCleveland, Ohio, Estados Unidos, 44106\n- Reclutamiento\n- Rainbow Babies and Childrens Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 216-844-5437\n-\nInvestigador principal:\n- Duncan S. Stearns\n-\nColumbus, Ohio, Estados Unidos, 43205\n- Reclutamiento\n- Nationwide Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 614-722-6039\n- Correo electr\u00f3nico:\n[Melinda.Triplet@nationwidechildrens.org](mailto:Melinda.Triplet@nationwidechildrens.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Mark A. Ranalli\n-\nDayton, Ohio, Estados Unidos, 45404\n- Reclutamiento\n- Dayton Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 800-228-4055\n-\nInvestigador principal:\n- Mukund G. Dole\n-\nToledo, Ohio, Estados Unidos, 43606\n- Reclutamiento\n- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 419-824-1842\n- Correo electr\u00f3nico:\n[PCIOncResearch@promedica.org](mailto:PCIOncResearch@promedica.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Jamie L. Dargart\n-\n-\nOklahoma\n-\nOklahoma City, Oklahoma, Estados Unidos, 73104\n- Reclutamiento\n- University of Oklahoma Health Sciences Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 405-271-8777\n- Correo electr\u00f3nico:\n[ou-clinical-trials@ouhsc.edu](mailto:ou-clinical-trials@ouhsc.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Rene Y. McNall-Knapp\n-\n-\nOregon\n-\nPortland, Oregon, Estados Unidos, 97227\n- Reclutamiento\n- Legacy Emanuel Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 503-413-2560\n-\nInvestigador principal:\n- Janice F. Olson\n-\nPortland, Oregon, Estados Unidos, 97239\n- Reclutamiento\n- Oregon Health and Science University\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 503-494-1080\n- Correo electr\u00f3nico:\n[trials@ohsu.edu](mailto:trials@ohsu.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Katrina Winsnes\n-\n-\nPennsylvania\n-\nAllentown, Pennsylvania, Estados Unidos, 18103\n- Reclutamiento\n- Lehigh Valley Hospital-Cedar Crest\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 610-402-9543\n- Correo electr\u00f3nico:\n[Morgan_M.Horton@lvhn.org](mailto:Morgan_M.Horton@lvhn.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Jacob A. Troutman\n-\nDanville, Pennsylvania, Estados Unidos, 17822\n- Reclutamiento\n- Geisinger Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 570-271-5251\n- Correo electr\u00f3nico:\n[HemonCCTrials@geisinger.edu](mailto:HemonCCTrials@geisinger.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Jagadeesh Ramdas\n-\nHershey, Pennsylvania, Estados Unidos, 17033\n- Reclutamiento\n- Penn State Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 717-531-6012\n-\nInvestigador principal:\n- Lisa M. McGregor\n-\nPhiladelphia, Pennsylvania, Estados Unidos, 19104\n- Reclutamiento\n- Children's Hospital of Philadelphia\n-\nInvestigador principal:\n- Suzanne P. MacFarland\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 267-425-5544\n- Correo electr\u00f3nico:\n[CancerTrials@email.chop.edu](mailto:CancerTrials@email.chop.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nPhiladelphia, Pennsylvania, Estados Unidos, 19134\n- Reclutamiento\n- Saint Christopher's Hospital for Children\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 215-427-8991\n-\nInvestigador principal:\n- Gregory E. Halligan\n-\nPittsburgh, Pennsylvania, Estados Unidos, 15224\n- Reclutamiento\n- Children's Hospital of Pittsburgh of UPMC\n-\nInvestigador principal:\n- Louis B. Rapkin\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 412-692-8570\n- Correo electr\u00f3nico:\n[jean.tersak@chp.edu](mailto:jean.tersak@chp.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\n-\nRhode Island\n-\nProvidence, Rhode Island, Estados Unidos, 02903\n- Reclutamiento\n- Rhode Island Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 401-444-1488\n-\nInvestigador principal:\n- Jennifer J. Welch\n-\n-\nSouth Carolina\n-\nCharleston, South Carolina, Estados Unidos, 29425\n- Reclutamiento\n- Medical University of South Carolina\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 843-792-9321\n- Correo electr\u00f3nico:\n[hcc-clinical-trials@musc.edu](mailto:hcc-clinical-trials@musc.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Jacqueline M. Kraveka\n-\nColumbia, South Carolina, Estados Unidos, 29203\n- Reclutamiento\n- Prisma Health Richland Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 864-241-6251\n-\nInvestigador principal:\n- Stuart L. Cramer\n-\nGreenville, South Carolina, Estados Unidos, 29605\n- Reclutamiento\n- BI-LO Charities Children's Cancer Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 864-241-6251\n-\nInvestigador principal:\n- Aniket Saha\n-\n-\nSouth Dakota\n-\nSioux Falls, South Dakota, Estados Unidos, 57117-5134\n- Reclutamiento\n- Sanford USD Medical Center - Sioux Falls\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 605-312-3320\n- Correo electr\u00f3nico:\n[OncologyClinicalTrialsSF@SanfordHealth.org](mailto:OncologyClinicalTrialsSF@SanfordHealth.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Kayelyn J. Wagner\n-\n-\nTennessee\n-\nKnoxville, Tennessee, Estados Unidos, 37916\n- Reclutamiento\n- East Tennessee Childrens Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 865-541-8266\n-\nInvestigador principal:\n- Susan E. Spiller\n-\nMemphis, Tennessee, Estados Unidos, 38105\n- Reclutamiento\n- Saint Jude Children's Research Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 888-226-4343\n- Correo electr\u00f3nico:\n[referralinfo@stjude.org](mailto:referralinfo@stjude.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Jessica Gartrell\n-\nNashville, Tennessee, Estados Unidos, 37232\n- Reclutamiento\n- Vanderbilt University/Ingram Cancer Center\n-\nInvestigador principal:\n- Daniel J. Benedetti\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 800-811-8480\n-\nNashville, Tennessee, Estados Unidos, 37203\n- Reclutamiento\n- The Children's Hospital at TriStar Centennial\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 615-342-1919\n-\nInvestigador principal:\n- Jennifer A. Domm\n-\n-\nTexas\n-\nAustin, Texas, Estados Unidos, 78723\n- Reclutamiento\n- Dell Children's Medical Center of Central Texas\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 512-628-1902\n- Correo electr\u00f3nico:\n[TXAUS-DL-SFCHemonc.research@ascension.org](mailto:TXAUS-DL-SFCHemonc.research@ascension.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Shannon M. Cohn\n-\nCorpus Christi, Texas, Estados Unidos, 78411\n- Reclutamiento\n- Driscoll Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 361-694-5311\n- Correo electr\u00f3nico:\n[Crystal.DeLosSantos@dchstx.org](mailto:Crystal.DeLosSantos@dchstx.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Nkechi I. Mba\n-\nDallas, Texas, Estados Unidos, 75390\n- Reclutamiento\n- UT Southwestern/Simmons Cancer Center-Dallas\n-\nInvestigador principal:\n- Jonathan E. Wickiser\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 214-648-7097\n- Correo electr\u00f3nico:\n[canceranswerline@UTSouthwestern.edu](mailto:canceranswerline@UTSouthwestern.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nDallas, Texas, Estados Unidos, 75230\n- Reclutamiento\n- Medical City Dallas Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 972-566-5588\n-\nInvestigador principal:\n- Stanton C. Goldman\n-\nEl Paso, Texas, Estados Unidos, 79905\n- Reclutamiento\n- El Paso Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 915-298-5444\n- Correo electr\u00f3nico:\n[ranjan.bista@ttuhsc.edu](mailto:ranjan.bista@ttuhsc.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Ranjan Bista\n-\nFort Worth, Texas, Estados Unidos, 76104\n- Reclutamiento\n- Cook Children's Medical Center\n-\nInvestigador principal:\n- Lauren J. Akers\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 682-885-2103\n- Correo electr\u00f3nico:\n[CookChildrensResearch@cookchildrens.org](mailto:CookChildrensResearch@cookchildrens.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nHouston, Texas, Estados Unidos, 77030\n- Reclutamiento\n- M D Anderson Cancer Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 877-632-6789\n- Correo electr\u00f3nico:\n[askmdanderson@mdanderson.org](mailto:askmdanderson@mdanderson.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Najat C. Daw\n-\nHouston, Texas, Estados Unidos, 77030\n- Reclutamiento\n- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center\n-\nInvestigador principal:\n- Sarah B. Whittle\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 713-798-1354\n- Correo electr\u00f3nico:\n[burton@bcm.edu](mailto:burton@bcm.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nLubbock, Texas, Estados Unidos, 79410\n- Reclutamiento\n- Covenant Children's Hospital\n-\n-\nInvestigador principal:\n- Kishor M. Bhende\n-\nLubbock, Texas, Estados Unidos, 79415\n- Reclutamiento\n- UMC Cancer Center / UMC Health System\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 806-775-8590\n-\nInvestigador principal:\n- Erin K. Barr\n-\nSan Antonio, Texas, Estados Unidos, 78207\n- Reclutamiento\n- Children's Hospital of San Antonio\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 210-704-2894\n- Correo electr\u00f3nico:\n[bridget.medina@christushealth.org](mailto:bridget.medina@christushealth.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Timothy C. Griffin\n-\nSan Antonio, Texas, Estados Unidos, 78229\n- Reclutamiento\n- University of Texas Health Science Center at San Antonio\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 210-450-3800\n- Correo electr\u00f3nico:\n[phoresearchoffice@uthscsa.edu](mailto:phoresearchoffice@uthscsa.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Anne-Marie R. Langevin\n-\nSan Antonio, Texas, Estados Unidos, 78229\n- Reclutamiento\n- Methodist Children's Hospital of South Texas\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 210-575-6240\n- Correo electr\u00f3nico:\n[Vinod.GidvaniDiaz@hcahealthcare.com](mailto:Vinod.GidvaniDiaz@hcahealthcare.com?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Jose M. Esquilin\n-\nTemple, Texas, Estados Unidos, 76508\n- Reclutamiento\n- Scott and White Memorial Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 254-724-5407\n-\nInvestigador principal:\n- Nicholas W. McGregor\n-\n-\nUtah\n-\nSalt Lake City, Utah, Estados Unidos, 84113\n- Reclutamiento\n- Primary Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 801-585-5270\n-\nInvestigador principal:\n- Matthew Dietz\n-\n-\nVermont\n-\nBurlington, Vermont, Estados Unidos, 05405\n- Reclutamiento\n- University of Vermont and State Agricultural College\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 802-656-8990\n- Correo electr\u00f3nico:\n[rpo@uvm.edu](mailto:rpo@uvm.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Jessica L. Heath\n-\n-\nVirginia\n-\nCharlottesville, Virginia, Estados Unidos, 22908\n- Reclutamiento\n- University of Virginia Cancer Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 434-243-6303\n- Correo electr\u00f3nico:\n[uvacancertrials@hscmail.mcc.virginia.edu](mailto:uvacancertrials@hscmail.mcc.virginia.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- William C. Petersen\n-\nFalls Church, Virginia, Estados Unidos, 22042\n- Reclutamiento\n- Inova Fairfax Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 703-208-6650\n- Correo electr\u00f3nico:\n[Stephanie.VanBebber@inova.org](mailto:Stephanie.VanBebber@inova.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Robin Y. Dulman\n-\nNorfolk, Virginia, Estados Unidos, 23507\n- Reclutamiento\n- Children's Hospital of The King's Daughters\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 757-668-7243\n- Correo electr\u00f3nico:\n[CCBDCresearch@chkd.org](mailto:CCBDCresearch@chkd.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Eric J. Lowe\n-\nPortsmouth, Virginia, Estados Unidos, 23708-2197\n- Reclutamiento\n- Naval Medical Center - Portsmouth\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 757-953-5939\n-\nInvestigador principal:\n- Bethany M. Mikles\n-\nRichmond, Virginia, Estados Unidos, 23298\n- Reclutamiento\n- Virginia Commonwealth University/Massey Cancer Center\n-\nContacto:\n- Site Public Contact\n- Correo electr\u00f3nico:\n[CTOclinops@vcu.edu](mailto:CTOclinops@vcu.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Frances Austin\n-\n-\nWashington\n-\nSeattle, Washington, Estados Unidos, 98105\n- Reclutamiento\n- Seattle Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 866-987-2000\n-\nInvestigador principal:\n- Sarah E. Leary\n-\nSpokane, Washington, Estados Unidos, 99204\n- Reclutamiento\n- Providence Sacred Heart Medical Center and Children's Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 800-228-6618\n- Correo electr\u00f3nico:\n[HopeBeginsHere@providence.org](mailto:HopeBeginsHere@providence.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Judy L. Felgenhauer\n-\nTacoma, Washington, Estados Unidos, 98405\n- Reclutamiento\n- Mary Bridge Children's Hospital and Health Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 253-403-1461\n- Correo electr\u00f3nico:\n[research@multicare.org](mailto:research@multicare.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Robert G. Irwin\n-\nTacoma, Washington, Estados Unidos, 98431\n- Reclutamiento\n- Madigan Army Medical Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 253-968-6144\n- Correo electr\u00f3nico:\n[Melissa.a.forouhar.mil@mail.mil](mailto:Melissa.a.forouhar.mil@mail.mil?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Melissa A. Forouhar\n-\n-\nWest Virginia\n-\nCharleston, West Virginia, Estados Unidos, 25304\n- Reclutamiento\n- West Virginia University Charleston Division\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 304-388-9944\n-\nInvestigador principal:\n- Mohamad H. Badawi\n-\nMorgantown, West Virginia, Estados Unidos, 26506\n- Reclutamiento\n- West Virginia University Healthcare\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 304-293-7374\n- Correo electr\u00f3nico:\n[cancertrialsinfo@hsc.wvu.edu](mailto:cancertrialsinfo@hsc.wvu.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Ashley E. Meyer\n-\n-\nWisconsin\n-\nMadison, Wisconsin, Estados Unidos, 53792\n- Reclutamiento\n- University of Wisconsin Carbone Cancer Center\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 800-622-8922\n-\nInvestigador principal:\n- Kenneth B. De Santes\n-\nMarshfield, Wisconsin, Estados Unidos, 54449\n- Reclutamiento\n- Marshfield Medical Center-Marshfield\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 800-782-8581\n- Correo electr\u00f3nico:\n[oncology.clinical.trials@marshfieldresearch.org](mailto:oncology.clinical.trials@marshfieldresearch.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\nInvestigador principal:\n- Jon M. Brandt\n-\nMilwaukee, Wisconsin, Estados Unidos, 53226\n- Reclutamiento\n- Children's Hospital of Wisconsin\n-\nInvestigador principal:\n- Angela Steineck\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 414-955-4727\n- Correo electr\u00f3nico:\n[MACCCTO@mcw.edu](mailto:MACCCTO@mcw.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery)\n-\n-\n-\nNueva Zelanda\n-\n-\nChristchurch, Nueva Zelanda, 8011\n- Reclutamiento\n- Christchurch Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 03 364 0640\n-\nInvestigador principal:\n- Amanda J. Lyver\n-\n-\nAuckland\n-\nGrafton, Auckland, Nueva Zelanda, 1145\n- Reclutamiento\n- Starship Children's Hospital\n-\nInvestigador principal:\n- Mark A. Winstanley\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 0800 728 436\n-\n-\n-\nPuerto Rico\n-\n-\nSan Juan, Puerto Rico, 00926\n- Reclutamiento\n- University Pediatric Hospital\n-\nContacto:\n- Site Public Contact\n- N\u00famero de tel\u00e9fono: 787-474-0333\n-\nInvestigador principal:\n- Maria E. Echevarria\n-\nSan Juan, Puerto Rico, 00912\n- Activo, no reclutando\n- San Jorge Children's Hospital\n-\n-\nCriterios de participaci\u00f3n\nCriterio de elegibilidad\nEdades elegibles para estudiar\nAcepta Voluntarios Saludables\nDescripci\u00f3n\nCriterios de inclusi\u00f3n:\n- Los pacientes del Grupo F deben tener un \u00e1rea de superficie corporal (BSA) >= 0,6 m^2\n- Los pacientes deben tener un estado funcional correspondiente a las puntuaciones del Grupo Oncol\u00f3gico Cooperativo del Este (ECOG) de 0, 1 o 2; use Karnofsky para pacientes > 16 a\u00f1os y Lansky para pacientes = < 16 a\u00f1os; los pacientes que no pueden caminar debido a la par\u00e1lisis, pero que est\u00e1n en una silla de ruedas, se considerar\u00e1n ambulatorios a efectos de evaluar la puntuaci\u00f3n de rendimiento\n- Los pacientes deben tener un diagn\u00f3stico reciente de neoplasias malignas hep\u00e1ticas pedi\u00e1tricas primarias comprobadas histol\u00f3gicamente, incluido el hepatoblastoma o el carcinoma hepatocelular, excepto como se indica a continuaci\u00f3n; los pacientes con diagn\u00f3stico de neoplasia hepatocelular, no especificada de otra manera, deben clasificarse y tratarse por brazos de tratamiento de hepatoblastoma; tenga en cuenta que en algunos casos se requiere una revisi\u00f3n r\u00e1pida de patolog\u00eda central; tenga en cuenta: todos los pacientes con histolog\u00eda evaluada por el pat\u00f3logo institucional compatible con HB pura de c\u00e9lulas peque\u00f1as indiferenciada (SCU) deber\u00e1n someterse a pruebas de INI1/SMARCB1 mediante inmunohistoqu\u00edmica (IHC) de acuerdo con las pr\u00e1cticas en la instituci\u00f3n\n- Los pacientes con histolog\u00eda compatible con SCU pura deben tener tinci\u00f3n INI1/SMARCB1 positiva\nPara todos los pacientes del Grupo A, el estado de WDF determinado por revisi\u00f3n r\u00e1pida se utilizar\u00e1 para estratificar a\u00fan m\u00e1s a los pacientes en el Grupo A1 o A2\n- Para los Grupos B, C y D, se requiere una revisi\u00f3n r\u00e1pida si los pacientes tienen >= 8 a\u00f1os de edad o tienen una alfafetoprote\u00edna (AFP) = < 100 en el momento del diagn\u00f3stico\n- Para todos los pacientes de los Grupos E y F, se requiere una revisi\u00f3n r\u00e1pida de patolog\u00eda central\nEn situaciones de emergencia, cuando un paciente cumple con todos los dem\u00e1s criterios de elegibilidad y ha tenido las observaciones iniciales requeridas, pero est\u00e1 demasiado enfermo para someterse a una biopsia de manera segura, el paciente puede inscribirse sin una biopsia.\nLas situaciones cl\u00ednicas en las que se puede indicar un tratamiento de emergencia incluyen, entre otras, las siguientes circunstancias:\n- Compromiso anat\u00f3mico o mec\u00e1nico de la funci\u00f3n de \u00f3rganos cr\u00edticos por el tumor (p. ej., dificultad/insuficiencia respiratoria, s\u00edndrome compartimental abdominal, obstrucci\u00f3n urinaria, etc.)\n- Coagulopat\u00eda incorregible\nPara que un paciente mantenga la elegibilidad para AHEP1531 cuando recibe tratamiento de emergencia, debe ocurrir lo siguiente:\n- El paciente debe tener un diagn\u00f3stico cl\u00ednico de hepatoblastoma, incluida una alfafetoprote\u00edna (AFP) elevada, y debe cumplir con todos los criterios de elegibilidad de AHEP1531 en el momento del tratamiento emergente.\n- El paciente debe estar inscrito en AHEP1531 antes de iniciar la terapia del protocolo; un paciente no ser\u00e1 elegible si se administra quimioterapia antes de la inscripci\u00f3n en AHEP1531\n- Nota: Si el paciente recibe quimioterapia con AHEP1531 de manera urgente ANTES de someterse a una biopsia diagn\u00f3stica, la revisi\u00f3n patol\u00f3gica del material obtenido en el futuro durante la biopsia o la resecci\u00f3n quir\u00fargica debe confirmar el diagn\u00f3stico de hepatoblastoma o no revelar otro diagn\u00f3stico patol\u00f3gico para incluirlo en el an\u00e1lisis de los objetivos del estudio\n- Los pacientes pueden haber tenido una resecci\u00f3n quir\u00fargica de la neoplasia maligna hep\u00e1tica antes de la inscripci\u00f3n; Se proh\u00edbe cualquier otra terapia contra el c\u00e1ncer para la lesi\u00f3n hep\u00e1tica actual.\nAclaramiento de creatinina o tasa de filtraci\u00f3n glomerular (TFG) de radiois\u00f3topos >= 60 ml/min/1,73 m ^ 2 o\nUna creatinina s\u00e9rica basada en la edad/g\u00e9nero de la siguiente manera:\n- Edad: creatinina s\u00e9rica m\u00e1xima (mg/dL)\n- 1 mes a < 6 meses: 0,4 (masculino y femenino)\n- 6 meses a < 1 a\u00f1o: 0,5 (masculino y femenino)\n- 1 a < 2 a\u00f1os: 06 (masculino y femenino)\n- 2 a < 6 a\u00f1os: 0,8 (masculino y femenino)\n- 6 a < 10 a\u00f1os: 1 (masculino y femenino)\n- 10 a < 13 a\u00f1os: 1,2 (masculino y femenino)\n- 13 a < 16 a\u00f1os: 1,5 (masculino), 1,4 (femenino)\n- >= 16 a\u00f1os: 1,7 (masculino), 1,4 (femenino)\n- Bilirrubina total =< 5 x l\u00edmite superior normal (LSN) para la edad\n- Aspartato aminotransferasa (AST) (transaminasa glut\u00e1mico-oxalac\u00e9tica s\u00e9rica [SGOT])/alanina aminotransferasa (ALT) (glutamato piruvato transaminasa s\u00e9rica [SGPT]) < 10 veces el l\u00edmite superior normal (LSN) para la edad\n- Fracci\u00f3n de acortamiento de >= 28 % por ecocardiograma (para pacientes con reg\u00edmenes que contienen doxorrubicina [Grupos C, D, E2 y F] evaluados dentro de las 8 semanas previas a la inscripci\u00f3n en el estudio) o\n- Fracci\u00f3n de eyecci\u00f3n de >= 47 % por ecocardiograma o angiograma con radion\u00faclidos (para pacientes con reg\u00edmenes que contienen doxorrubicina [Grupos C, D, E2 y F] evaluados dentro de las 8 semanas anteriores a la inscripci\u00f3n en el estudio)\n- Solo pacientes del grupo F: intervalo QT/QT corregido (QTc) = < 450 milisegundos para hombres y = < 470 milisegundos para mujeres (evaluado dentro de las 8 semanas anteriores a la inscripci\u00f3n en el estudio)\n- Pruebas de funci\u00f3n pulmonar normales (incluida la capacidad de difusi\u00f3n del mon\u00f3xido de carbono [DLCO] del pulm\u00f3n) si existe una indicaci\u00f3n cl\u00ednica para la determinaci\u00f3n (p. disnea en reposo, requerimiento conocido de ox\u00edgeno suplementario) (para pacientes que reciben quimioterapia [Grupos A, B, C, D, E2, F]); para pacientes que no tienen s\u00edntomas respiratorios o necesidad de ox\u00edgeno suplementario, NO se requieren pruebas de funci\u00f3n pulmonar (PFT)\n- Todos los pacientes y/o sus padres o tutores legales deben firmar un consentimiento informado por escrito\n- Se deben cumplir todos los requisitos institucionales, de la Administraci\u00f3n de Alimentos y Medicamentos (FDA) y del Instituto Nacional del C\u00e1ncer (NCI) para estudios en humanos.\nCriterio de exclusi\u00f3n:\n- Quimioterapia previa o terapia dirigida al tumor (es decir, radioterapia, agentes biol\u00f3gicos, terapia local (embolizaci\u00f3n, ablaci\u00f3n por radiofrecuencia y l\u00e1ser); por lo tanto, los pacientes con un s\u00edndrome de predisposici\u00f3n que tienen una neoplasia maligna previa no son elegibles\n- Pacientes que actualmente est\u00e1n recibiendo otro f\u00e1rmaco en investigaci\u00f3n\n- Pacientes que actualmente est\u00e1n recibiendo otros agentes anticancer\u00edgenos\n- Pacientes con infecci\u00f3n no controlada\n- Pacientes que recibieron previamente un trasplante de \u00f3rgano s\u00f3lido, distintos de aquellos que recibieron previamente un trasplante hep\u00e1tico ortot\u00f3pico (OLT) como tratamiento primario de su carcinoma hepatocelular\n- Pacientes con hipersensibilidad a cualquier f\u00e1rmaco en su grupo de tratamiento esperado\n- Grupo C: pacientes con deficiencia conocida de dihidropirimidina deshidrogenasa (DPD)\nGrupo D:\n- Pacientes con enfermedad inflamatoria intestinal cr\u00f3nica y/u obstrucci\u00f3n intestinal\n- Pacientes con uso concomitante de hierba de San Juan, que no se puede suspender antes del inicio del tratamiento de prueba\nGrupo F:\n- Pacientes con neuropat\u00eda sensitiva perif\u00e9rica con deterioro funcional\n- Pacientes con antecedentes personales o familiares de s\u00edndrome de QT largo cong\u00e9nito\nEstos criterios se aplican \u00daNICAMENTE a los pacientes que pueden recibir quimioterapia (todos los grupos excepto el Grupo E1):\n- Pacientes de sexo femenino que est\u00e1n embarazadas debido a que se han observado toxicidades fetales y efectos teratog\u00e9nicos para varios de los f\u00e1rmacos del estudio; se requiere una prueba de embarazo para pacientes mujeres en edad f\u00e9rtil\n- Mujeres lactantes que planean amamantar a sus beb\u00e9s\nPacientes sexualmente activas con potencial reproductivo que no han aceptado usar un m\u00e9todo anticonceptivo eficaz durante la duraci\u00f3n de su participaci\u00f3n en el estudio\n- Nota para el Grupo F: las pacientes en edad f\u00e9rtil deben utilizar un m\u00e9todo anticonceptivo eficaz durante el tratamiento con sorafenib y durante al menos 2 semanas despu\u00e9s de suspender el tratamiento.\nPlan de estudios\n\u00bfC\u00f3mo est\u00e1 dise\u00f1ado el estudio?\nDetalles de dise\u00f1o\n- Prop\u00f3sito principal: Tratamiento\n- Asignaci\u00f3n: Aleatorizado\n- Modelo Intervencionista: Asignaci\u00f3n paralela\n- Enmascaramiento: Ninguno (etiqueta abierta)\nArmas e Intervenciones\n|\n|\nGrupo de participantes/brazo\n|\n|\nIntervenci\u00f3n / Tratamiento\n|\n|\nComparador activo: Grupo A1 (WDF)\nLos pacientes se someten a observaci\u00f3n.\n|\n|\nEstudios correlativos\nSometerse a una espera vigilante\nOtros nombres:\n|\n|\nExperimental: GRUPO A2 (SIN WDF)\nLos pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1 despu\u00e9s de la cirug\u00eda. El tratamiento se repite cada 21 d\u00edas hasta por 2 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable.\n|\n|\nEstudios correlativos\nDado IV\nOtros nombres:\n|\n|\nExperimental: GRUPO B1 BRAZO 4-CDDP\nLos pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1. El tratamiento se repite cada 14 d\u00edas durante 4 ciclos (2 preoperatorios, 2 posoperatorios) en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable.\n|\n|\nEstudios correlativos\nDado IV\nOtros nombres:\n|\n|\nExperimental: GRUPO B1 BRAZO 6-CDDP\nLos pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1. El tratamiento se repite cada 14 d\u00edas durante 6 ciclos (2 preoperatorios, 4 posoperatorios) en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable.\n|\n|\nEstudios correlativos\nDado IV\nOtros nombres:\nSometerse a una resecci\u00f3n quir\u00fargica\nOtros nombres:\n|\n|\nExperimental: GRUPO B2 BRAZO I\nLos pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1. El tratamiento se repite cada 14 d\u00edas hasta un total de 6 ciclos (4 antes de la cirug\u00eda, 2 despu\u00e9s de la cirug\u00eda). Despu\u00e9s del ciclo 4, los pacientes se someten a cirug\u00eda y luego contin\u00faan con 2 ciclos adicionales de cisplatino.\n|\n|\nEstudios correlativos\nDado IV\nOtros nombres:\nSometerse a una resecci\u00f3n quir\u00fargica\nOtros nombres:\n|\n|\nExperimental: GRUPO B2 BRAZO II\nLos pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1. El tratamiento se repite cada 14 d\u00edas hasta un total de 6 ciclos.\n|\n|\nEstudios correlativos\nDado IV\nOtros nombres:\n|\n|\nExperimental: GRUPO C BRAZO C5VD\nLos pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1, 5-fluorouracilo IV durante 1 a 15 minutos, sulfato de vincristina IV durante 1 minuto los d\u00edas 1, 8 y 15 y doxorrubicina IV durante 1 a 15 minutos los d\u00edas 1 y 2. Tratamiento se repite cada 21 d\u00edas hasta por 6 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable. Los pacientes se someten a cirug\u00eda despu\u00e9s del ciclo 2 o 4.\n|\n|\nEstudios correlativos\nDado IV\nOtros nombres:\nDado IV\nOtros nombres:\nDado IV\nOtros nombres:\nDado IV\nOtros nombres:\n|\n|\nExperimental: GRUPO C BRAZO CDDP\nLos pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1. El tratamiento se repite cada 14 d\u00edas hasta por 6 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable. Los pacientes se someten a cirug\u00eda despu\u00e9s del ciclo 2 o 4.\n|\n|\nEstudios correlativos\nDado IV\nOtros nombres:\nSometerse a una resecci\u00f3n quir\u00fargica\nOtros nombres:\n|\n|\nExperimental: GRUPO D1\nINDUCCI\u00d3N DE SIOPEL-4: los pacientes reciben cisplatino IV durante 6 horas los d\u00edas 1, 8 y 15 (para los ciclos 1 y 2) y los d\u00edas 1 y 8 (para el ciclo 3) y doxorrubicina IV durante 1 a 15 minutos los d\u00edas 8 y 9 durante los ciclos 1 y 2 y los d\u00edas 1 y 2 durante el ciclo 3. El tratamiento se repite cada 28 d\u00edas hasta por 3 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable.\nCONSOLIDACI\u00d3N: Los pacientes con remisi\u00f3n pulmonar completa (ya sea con quimioterapia y/o cirug\u00eda) reciben carboplatino IV durante 1 hora el d\u00eda 1 y doxorrubicina IV durante 1 a 15 minutos los d\u00edas 1 y 2. El tratamiento se repite cada 21 d\u00edas hasta 3 ciclos en la ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable.\n|\n|\nEstudios correlativos\nDado IV\nOtros nombres:\nDado IV\nOtros nombres:\nDado IV\nOtros nombres:\n|\n|\nExperimental: GRUPO D2 BRAZO CE\nSIOPEL-4 IV INDUCCI\u00d3N: Los pacientes reciben cisplatino IV durante 6 horas los d\u00edas 1, 8 y 15 (para los ciclos 1 y 2) y los d\u00edas 1 y 8 (para el ciclo 3) y doxorrubicina IV durante 1 a 15 minutos los d\u00edas 8 y 9. El tratamiento se repite cada 28 d\u00edas hasta por 3 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable.\nLos pacientes reciben carboplatino IV durante 1 hora los d\u00edas 1 y 2, doxorrubicina IV durante 1-15 minutos los d\u00edas 1 y 2 durante los ciclos 1, 3 y 5, y carboplatino durante 1 hora y etop\u00f3sido IV durante 2 horas los d\u00edas 1 y 2 de ciclos 2, 4 y 6. Los tratamientos se repiten cada 21 d\u00edas hasta por 6 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable.\n|\n|\nEstudios correlativos\nDado IV\nOtros nombres:\nDado IV\nOtros nombres:\nDado IV\nOtros nombres:\nDado IV\nOtros nombres:\n|\n|\nExperimental: GRUPO D2 BRAZO VI\nSIOPEL-4 IV INDUCCI\u00d3N: Los pacientes reciben cisplatino IV durante 6 horas los d\u00edas 1, 8 y 15 (para los ciclos 1 y 2) y los d\u00edas 1 y 8 (para el ciclo 3) y doxorrubicina IV durante 1 a 15 minutos los d\u00edas 8 y 9. El tratamiento se repite cada 28 d\u00edas hasta por 3 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable.\nLos pacientes reciben carboplatino IV durante 1 hora los d\u00edas 1 y 2 y doxorrubicina IV durante 1-15 minutos los d\u00edas 1 y 2 durante los ciclos 1, 3 y 5. Los pacientes tambi\u00e9n reciben sulfato de vincristina IV durante 1 minuto los d\u00edas 1 y 8 e irinotec\u00e1n IV durante 90 minutos QD en los d\u00edas 1 a 5 de los ciclos 2, 4 y 6. Los tratamientos se repiten cada 21 d\u00edas hasta por 6 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable.\n|\n|\nEstudios correlativos\nDado IV\nOtros nombres:\nDado IV\nOtros nombres:\nDado IV\nOtros nombres:\nDado IV\nOtros nombres:\nDado IV\n|\n|\nComparador activo: GRUPO E1\nLos pacientes solo se someten a observaci\u00f3n.\n|\n|\nEstudios correlativos\nDado IV\nOtros nombres:\nSometerse a una espera vigilante\nOtros nombres:\n|\n|\nExperimental: GRUPO E2 (PLADO)\nLos pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1 y doxorrubicina IV durante 1-15 minutos los d\u00edas 1 y 2 despu\u00e9s de la cirug\u00eda. Los tratamientos se repiten cada 21 d\u00edas durante 4 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable.\n|\n|\nEstudios correlativos\nDado IV\nOtros nombres:\nDado IV\nOtros nombres:\n|\n|\nExperimental: GRUPO GRANJA 1 (PLADO)\nLos pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1, doxorrubicina IV durante 1-15 minutos los d\u00edas 1 y 2 y sorafenib PO BID los d\u00edas 3-21. Los tratamientos se repiten cada 21 d\u00edas hasta por 3 ciclos en ausencia de progresi\u00f3n de la enfermedad o toxicidad inaceptable. Los pacientes pueden someterse a cirug\u00eda, si los tumores son resecables, o recibir 3 ciclos adicionales del tratamiento.\n|\n|\nEstudios correlativos\nDado IV\nOtros nombres:\nDado IV\nOtros nombres:\nOrden de compra dada\nOtros nombres:\n|\n|\nExperimental: GRUPO GRANJA BRAZO 2 (P/GEMOX)\nLos pacientes reciben cisplatino IV durante 6 horas el d\u00eda 1, doxorrubicina IV durante 1-15 minutos los d\u00edas 1 y 2 y sorafenib PO BID los d\u00edas 3-14 de los ciclos 1 y 3. Los pacientes tambi\u00e9n reciben gemcitabina IV durante 90 minutos el d\u00eda 1, oxaliplatino IV durante 2 horas el d\u00eda 1 y sorafenib VO los d\u00edas 1 a 14 de los ciclos 2 y 4. Los pacientes pueden someterse a cirug\u00eda, si los tumores son resecables, o recibir 4 ciclos adicionales del tratamiento.\n|\n|\nEstudios correlativos\nDado IV\nOtros nombres:\nDado IV\nOtros nombres:\nDado IV\nOtros nombres:\nDado IV\nOtros nombres:\nOrden de compra dada\nOtros nombres:\nSometerse a una resecci\u00f3n quir\u00fargica\nOtros nombres:\n\u00bfQu\u00e9 mide el estudio?\nMedidas de resultado primarias\n|\n|\nMedida de resultado\n|\n|\nMedida Descripci\u00f3n\n|\n|\nPeriodo de tiempo\n|\n|\nSupervivencia libre de eventos (EFS)\nPeriodo de tiempo: 3 a\u00f1os\n|\n|\nLa SLE se define como el tiempo desde la aleatorizaci\u00f3n (o el registro en el ensayo para pacientes no aleatorizados) hasta el primer evento de falla donde los eventos de falla se definen como: progresi\u00f3n de la enfermedad existente o aparici\u00f3n de la enfermedad en nuevos sitios, muerte por cualquier causa anterior a la progresi\u00f3n de la enfermedad o al diagn\u00f3stico de una segunda neoplasia maligna. Los pacientes que no hayan tenido un evento ser\u00e1n censurados en su \u00faltima fecha de seguimiento. Se presentar\u00e1 EFS para el grupo A, grupo B1, grupo C, grupo D1, grupo D2 y E.\n|\n|\n3 a\u00f1os\n|\n|\nPorcentaje de participantes del Grupo B2 con tumores resecables\nPeriodo de tiempo: 6 meses\n|\n|\nLos pacientes del Grupo B que son irresecables despu\u00e9s de los ciclos 1 y 2 de tratamiento con cisplatino ser\u00e1n asignados al Grupo B2. Estos pacientes recibir\u00e1n ciclos 3-6 de tratamiento con cisplatino.\n|\n|\n6 meses\n|\n|\nTasa de respuesta para pacientes del Grupo F\nPeriodo de tiempo: Hasta 5 a\u00f1os\n|\n|\nLa respuesta se define como una respuesta completa (CR) o parcial (PR) seg\u00fan los criterios de la versi\u00f3n 1.1 de los Criterios de evaluaci\u00f3n de respuesta en tumores s\u00f3lidos (RECIST). Pacientes que no son evaluables para la respuesta, p. debido a la interrupci\u00f3n prematura del tratamiento o la muerte, se clasificar\u00e1n como no respondedores.\n|\n|\nHasta 5 a\u00f1os\nOtras medidas de resultado\n|\n|\nMedida de resultado\n|\n|\nMedida Descripci\u00f3n\n|\n|\nPeriodo de tiempo\n|\n|\nSupervivencia libre de fallas\nPeriodo de tiempo: 3 a\u00f1os\n|\n|\nLa supervivencia libre de fallas se define como el tiempo desde la aleatorizaci\u00f3n (o el registro en el ensayo para pacientes no aleatorizados) hasta el primer evento de falla. Los eventos de falla son: progresi\u00f3n de la enfermedad existente o aparici\u00f3n de la enfermedad en nuevos sitios, muerte por cualquier causa antes de la progresi\u00f3n de la enfermedad, diagn\u00f3stico de una segunda neoplasia maligna o falta de resecci\u00f3n.\n|\n|\n3 a\u00f1os\n|\n|\nSobrevivencia promedio\nPeriodo de tiempo: 3 a\u00f1os\n|\n|\nLa supervivencia general se define como el tiempo desde la aleatorizaci\u00f3n (o el registro de pacientes no aleatorizados) hasta la muerte por cualquier causa.\n|\n|\n3 a\u00f1os\n|\n|\nPorcentaje de pacientes que experimentaron eventos adversos de grado 3 o superior\nPeriodo de tiempo: 8 meses\n|\n|\nSe informar\u00e1 el porcentaje de pacientes que experimentan toxicidad de grado 3 o superior, donde los eventos adversos se califican de acuerdo con los Criterios de Terminolog\u00eda Com\u00fan para Eventos Adversos del Instituto Nacional del C\u00e1ncer, versi\u00f3n 4.0.\n|\n|\n8 meses\n|\n|\nPorcentaje de pacientes con cardiotoxicidad, nefrotoxicidad y ototoxicidad relacionadas con la quimioterapia\nPeriodo de tiempo: Hasta 5 a\u00f1os\n|\n|\nLos eventos adversos se clasifican de acuerdo con los Criterios de Terminolog\u00eda Com\u00fan para Eventos Adversos del Instituto Nacional del C\u00e1ncer, versi\u00f3n 4.0.\n|\n|\nHasta 5 a\u00f1os\n|\n|\nPorcentaje de pacientes con p\u00e9rdida auditiva\nPeriodo de tiempo: Hasta 5 a\u00f1os\n|\n|\nLa p\u00e9rdida de audici\u00f3n se medir\u00e1 de acuerdo con la Escala SIOP de Boston para ototoxicidad.\n|\n|\nHasta 5 a\u00f1os\n|\n|\nMejor respuesta\nPeriodo de tiempo: Hasta 5 a\u00f1os\n|\n|\nLa respuesta en el carcinoma hepatocelular (CHC) se definir\u00e1 como una respuesta completa (CR) o parcial (PR) de acuerdo con los criterios de la versi\u00f3n 1.1 de los Criterios de evaluaci\u00f3n de la respuesta en tumores s\u00f3lidos (RECIST). La respuesta en HB se definir\u00e1 como RC o PR seg\u00fan la respuesta radiol\u00f3gica (RECIST v1.1) y la disminuci\u00f3n de AFP.\n|\n|\nHasta 5 a\u00f1os\n|\n|\nPorcentaje de participantes que son quir\u00fargicamente resecables\nPeriodo de tiempo: Hasta 5 a\u00f1os\n|\n|\nLa resecabilidad quir\u00fargica se define como resecci\u00f3n completa, resecci\u00f3n parcial o trasplante despu\u00e9s de la aleatorizaci\u00f3n (o inscripci\u00f3n para pacientes no aleatorizados).\n|\n|\nHasta 5 a\u00f1os\n|\n|\nPorcentaje de participantes con adherencia a las gu\u00edas quir\u00fargicas\nPeriodo de tiempo: Hasta 5 a\u00f1os\n|\n|\nLa adherencia a las gu\u00edas quir\u00fargicas se define como la decisi\u00f3n quir\u00fargica del m\u00e9dico local de resecar o no en comparaci\u00f3n con las gu\u00edas quir\u00fargicas actuales de SIOPEL.\n|\n|\nHasta 5 a\u00f1os\nColaboradores e Investigadores\nPatrocinador\nColaboradores\nInvestigadores\n- Investigador principal: Gregory M Tiao, Children's Oncology Group\nFechas de registro del estudio\nFechas importantes del estudio\nInicio del estudio (Actual)\nFinalizaci\u00f3n primaria (Estimado)\nFinalizaci\u00f3n del estudio (Estimado)\nFechas de registro del estudio\nEnviado por primera vez\nPrimero enviado que cumpli\u00f3 con los criterios de control de calidad\nPublicado por primera vez (Actual)\nActualizaciones de registros de estudio\n\u00daltima actualizaci\u00f3n publicada (Actual)\n\u00daltima actualizaci\u00f3n enviada que cumpli\u00f3 con los criterios de control de calidad\n\u00daltima verificaci\u00f3n\nM\u00e1s informaci\u00f3n\nT\u00e9rminos relacionados con este estudio\nT\u00e9rminos MeSH relevantes adicionales\n-\n[Enfermedades del Sistema Digestivo](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Digestive%20System%20Diseases)\n-\n[Neoplasias por tipo histol\u00f3gico](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Histologic%20Type)\n-\n[Neoplasias por sitio](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Site)\n-\n[Neoplasias Glandulares y Epiteliales](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Neoplasms%2C%20Glandular%20and%20Epithelial)\n-\n[Neoplasias del Sistema Digestivo](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Digestive%20System%20Neoplasms)\n-\n[Enfermedades del HIGADO](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Liver%20Diseases)\n-\n[Neoplasias Complejas y Mixtas](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Neoplasms%2C%20Complex%20and%20Mixed)\n-\n[Neoplasias](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Neoplasms)\n-\n[Carcinoma](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Carcinoma)\n-\n[Neoplasias Hepaticas](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Liver%20Neoplasms)\n-\n[Hepatoblastoma](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hepatoblastoma)\n-\n[Efectos fisiol\u00f3gicos de las drogas](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Physiological%20Effects%20of%20Drugs)\n-\n[Mecanismos moleculares de acci\u00f3n farmacol\u00f3gica](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Molecular%20Mechanisms%20of%20Pharmacological%20Action)\n-\n[Inhibidores de enzimas](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Enzyme%20Inhibitors)\n-\n[Antimetabolitos, Antineopl\u00e1sicos](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Antimetabolites%2C%20Antineoplastic)\n-\n[Antimetabolitos](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Antimetabolites)\n-\n[Agentes antineopl\u00e1sicos](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Antineoplastic%20Agents)\n-\n[Agentes inmunosupresores](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Immunosuppressive%20Agents)\n-\n[Factores inmunol\u00f3gicos](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Immunologic%20Factors)\n-\n[Moduladores de tubulina](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Tubulin%20Modulators)\n-\n[Agentes antimit\u00f3ticos](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Antimitotic%20Agents)\n-\n[Moduladores de mitosis](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Mitosis%20Modulators)\n-\n[Agentes antineopl\u00e1sicos, fitog\u00e9nicos](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Antineoplastic%20Agents%2C%20Phytogenic)\n-\n[Inhibidores de la topoisomerasa II](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Topoisomerase%20II%20Inhibitors)\n-\n[Inhibidores de la topoisomerasa](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Topoisomerase%20Inhibitors)\n-\n[Agentes dermatol\u00f3gicos](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Dermatologic%20Agents)\n-\n[Inhibidores de la prote\u00edna quinasa](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Protein%20Kinase%20Inhibitors)\n-\n[Antibi\u00f3ticos, Antineopl\u00e1sicos](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Antibiotics%2C%20Antineoplastic)\n-\n[Agentes queratol\u00edticos](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Keratolytic%20Agents)\n-\n[Inhibidores de la topoisomerasa I](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Topoisomerase%20I%20Inhibitors)\n-\n[Carboplatino](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin)\n-\n[Etop\u00f3sido](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Etoposide)\n-\n[Fosfato de etop\u00f3sido](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Etoposide%20phosphate)\n-\n[Cisplatino](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin)\n-\n[Fluorouracilo](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Fluorouracil)\n-\n[Sorafenib](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Sorafenib)\n-\n[Oxaliplatino](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Oxaliplatin)\n-\n[Podofilotoxina](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Podophyllotoxin)\n-\n[Irinotec\u00e1n](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Irinotecan)\n-\n[Doxorrubicina](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Doxorubicin)\n-\n[Doxorrubicina liposomal](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Liposomal%20doxorubicin)\n-\n[Vincristina](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Vincristine)\n-\n[Daunorrubicina](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Daunorubicin)\n-\n[Gemcitabina](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Gemcitabine)\nOtros n\u00fameros de identificaci\u00f3n del estudio\n- AHEP1531 (Otro identificador: CTEP)\n- U10CA180886 (Subvenci\u00f3n/contrato del NIH de EE. UU.)\n- NCI-2017-01910 (Identificador de registro: CTRP (Clinical Trial Reporting Program))\nInformaci\u00f3n sobre medicamentos y dispositivos, documentos del estudio\nEstudia un producto farmac\u00e9utico regulado por la FDA de EE. UU.\nEstudia un producto de dispositivo regulado por la FDA de EE. UU.\nEsta informaci\u00f3n se obtuvo directamente del sitio web\n[clinicaltrials.gov](https://clinicaltrials.gov) sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comun\u00edquese con [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). Tan pronto como se implemente un cambio en [clinicaltrials.gov](https://clinicaltrials.gov), tambi\u00e9n se actualizar\u00e1 autom\u00e1ticamente en nuestro sitio web. .\nEnsayos cl\u00ednicos sobre Hepatoblastoma\n-\nNCT05763173ReclutamientoHepatoblastoma | Radiolog\u00eda\n-\nNCT05756660ReclutamientoOtotoxicidad, inducida por f\u00e1rmacos\n-\nNCT05640960Reclutamiento\n-\nNCT05556642Reclutamiento\n[Hepatoblastoma en reca\u00edda y refractario: un registro prospectivo e iniciativa del consorcio de investigaci\u00f3n de tumores hep\u00e1ticos](https://ichgcp.net/es/clinical-trials-registry/NCT05556642)Hepatoblastoma refractario | Hepatoblastoma en reca\u00edda\n-\nNCT05322187A\u00fan no reclutando\n[Inhibidor secuencial de PD-1/PD-L1 y LENvatinib en TLCT y hepatoblastoma refractario despu\u00e9s de quimioterapia (sPLENTY-pc)](https://ichgcp.net/es/clinical-trials-registry/NCT05322187)C\u00e1ncer pedi\u00e1trico | C\u00e1ncer de h\u00edgado | Hepatoblastoma | Tumor s\u00f3lido pedi\u00e1trico | Tumor de c\u00e9lulas de transici\u00f3n\n-\nNCT05245123ReclutamientoNeuroblastoma | Hepatoblastoma | Nefroblastoma\n-\nNCT05170282Reclutamiento\n[Radi\u00f3mica de im\u00e1genes de resonancia magn\u00e9tica de aprendizaje profundo para el valor diagn\u00f3stico de tumores hep\u00e1ticos en beb\u00e9s](https://ichgcp.net/es/clinical-trials-registry/NCT05170282)Hepatoblastoma | Hemangioendotelioma hep\u00e1tico\n-\nNCT04928677Reclutamiento\n[Un estudio de codrituzumab en ni\u00f1os y adultos j\u00f3venes con tumores s\u00f3lidos que no respondieron al tratamiento o regresaron despu\u00e9s del tratamiento](https://ichgcp.net/es/clinical-trials-registry/NCT04928677)Tumor s\u00f3lido extracraneal primario | Glypican 3 recurrente o refractario (GPC3)\n-\nNCT04901702Reclutamiento\n[Estudio de Onivyde con talazoparib o temozolomida en ni\u00f1os con tumores s\u00f3lidos recurrentes y sarcoma de Ewing](https://ichgcp.net/es/clinical-trials-registry/NCT04901702)Neoplasia s\u00f3lida maligna refractaria | Sarcoma de Ewing recurrente | Hepatoblastoma recurrente | Tumor maligno de c\u00e9lulas germinales recidivante | Neoplasia s\u00f3lida maligna recurrente | Neuroblastoma recurrente | Osteosarcoma recurrente | Tumor neuroectod\u00e9rmico primitivo perif\u00e9rico recidivante | Tumor rabdoide recurrente | Rabdomiosarcoma recurrente\n-\nNCT04897321Reclutamiento\n[Terapia aut\u00f3loga de c\u00e9lulas T con receptor de ant\u00edgeno quim\u00e9rico espec\u00edfico B7-H3 para pacientes pedi\u00e1tricos con tumores s\u00f3lidos (3CAR)](https://ichgcp.net/es/clinical-trials-registry/NCT04897321)Melanoma | Sarcoma de tejido blando | Carcinoma | Osteosarcoma | Sarcoma de Ewing | Tumor rabdoide | Neuroblastoma | Rabdomiosarcoma | Tumor de Wilms | Hepatoblastoma\nEnsayos cl\u00ednicos sobre An\u00e1lisis de biomarcadores de laboratorio\n-\nNCT05558904Reclutamiento\n-\nNCT05428852ReclutamientoMet\u00e1stasis Cerebral, Adulto\n-\nNCT05396859Reclutamiento\n[Entrectinib en combinaci\u00f3n con ASTX727 para el tratamiento de la leucemia mieloide aguda con mutaci\u00f3n en TP53 en reca\u00edda o refractaria](https://ichgcp.net/es/clinical-trials-registry/NCT05396859)Leucemia mieloide aguda | Leucemia mieloide aguda recurrente | Leucemia mieloide aguda refractaria\n-\nNCT05388773Reclutamiento\n-\nNCT05213585ReclutamientoEl enfoque del estudio es evaluar la eficacia de la ivermectina t\u00f3pica para eliminar las pesta\u00f1as postizas\n-\nNCT05212428Reclutamiento\n-\nNCT05103904Reclutamiento\n[Lenvatinib para el tratamiento del carcinoma hepatocelular recidivante despu\u00e9s de un trasplante de h\u00edgado](https://ichgcp.net/es/clinical-trials-registry/NCT05103904)Carcinoma hepatocelular irresecable | Carcinoma hepatocelular recidivante | Carcinoma hepatocelular en estadio III AJCC v8 | Carcinoma hepatocelular en estadio IIIA AJCC v8 | Carcinoma hepatocelular en estadio IV AJCC v8 | Carcinoma hepatocelular en estadio IVA AJCC v8 | Carcinoma hepatocelular en estadio IVB AJCC v8 | Carcinoma hepatocelular en estadio IIIB AJCC v8\n-\nNCT05071859Reclutamiento\n[Superposici\u00f3n gen\u00e9tica entre anomal\u00edas y c\u00e1ncer en ni\u00f1os del grupo de oncolog\u00eda infantil: el estudio COG GOBACK](https://ichgcp.net/es/clinical-trials-registry/NCT05071859)C\u00e1ncer pedi\u00e1trico | Anomal\u00eda congenital\n-\nNCT05046080ReclutamientoAdenocarcinoma de cuello uterino independiente del virus del papiloma humano, tipo de c\u00e9lulas claras\n-\nNCT04977024Reclutamiento\n[Vacuna SARS-CoV-2 (COH04S1) versus vacuna EUA SARS-COV-2 para el tratamiento de COVID-19 en pacientes con c\u00e1ncer de sangre](https://ichgcp.net/es/clinical-trials-registry/NCT04977024)Linfoma | Leucemia | Mieloma de c\u00e9lulas plasm\u00e1ticas | Neoplasia del sistema hematopoy\u00e9tico y linfoide | Contagio de COVID-19", "language": null, "image": null, "pagetype": "website", "links": ["https://ichgcp.net/es", "#", "https://ichgcp.net/de", "https://ichgcp.net/", "https://ichgcp.net/es", "https://ichgcp.net/fr", "https://ichgcp.net/it", "https://ichgcp.net/pt", "https://ichgcp.net/ru", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/ich-e-group-of-guidelines", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/events", "https://ichgcp.net/es/clinical-trials-registry/publications", "https://ichgcp.net/es/clinical-trials-registry/researchers", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/clinical-trials-registry/NCT03533582", "https://telegram.me/share/url?url=https://ichgcp.net/es/clinical-trials-registry/NCT03533582&text=", "https://twitter.com/intent/tweet?url=https://ichgcp.net/es/clinical-trials-registry/NCT03533582", "https://ichgcp.net/es", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Children%27s%20Oncology%20Group", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hepatoblastoma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Fibrolamellar%20Carcinoma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Childhood%20Hepatocellular%20Carcinoma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Childhood%20Malignant%20Liver%20Neoplasm", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hepatocellular%20Malignant%20Neoplasm%2C%20Not%20Otherwise%20Specified", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Laboratory%20Biomarker%20Analysis", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Etoposide", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Gemcitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Vincristine%20Sulfate", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Doxorubicin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Fluorouracil", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Oxaliplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Irinotecan", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Sorafenib", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Resection", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Patient%20Observation", "mailto:Jordan.Hansford@rch.org.au?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:helpdesk@childrensoncologygroup.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:research4kids@ucalgary.ca?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:pedsoncologyresearch@ahs.ca?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:ctu_web@cancercare.mb.ca?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Research@iwk.nshealth.ca?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:cc-clinicaltrials@kgh.kari.net?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:ask.CRS@sickkids.ca?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:info@thechildren.com?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:yvan.samson@umontreal.ca?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:oncologyresearch@peds.uab.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:AKPAMC.OncologyResearchSupport@providence.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Research@valleychildrens.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Kpoct@kp.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Carla.Golden@ucsf.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:oncresearch@choc.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:ccto-office@stanford.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Melanie.Cook@sutterhealth.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:cancertrials@ucsf.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:josh.b.gordon@nsmtp.kp.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:canceranswers@yale.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Allison.bruce@nemours.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:molly.arnstrom@leehealth.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:cancer-center@ufl.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:OHR@mhs.net?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Allison.bruce@nemours.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Jennifer.spinelli@orlandohealth.com?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Allison.bruce@nemours.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:FH.Cancer.Research@flhosp.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:eebrou@ascension.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Ashley.Repp@jhmi.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:syapchanyk@tgh.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:jennifer.manns@baycare.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Leann.Schilling@choa.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:ga_cares@augusta.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Lorraine.OHara@hcahealthcare.com?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:eslinget@slhs.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:cancerclinicaltrials@bsd.uchicago.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:helpdesk@childrensoncologygroup.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:research@stvincent.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:samantha.mallory@unitypoint.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:CancerResource@nortonhealthcare.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:CHResearch@lcmchealth.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Elisemarie.curry@ochsner.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:sverwys@mmc.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:jhcccro@jhmi.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:pridgely@lifebridgehealth.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:tamara.wrenn@baystatehealth.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:helpdesk@childrensoncologygroup.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:crcwm-regulatory@crcwm.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:crcwm-regulatory@crcwm.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:helpdesk@childrensoncologygroup.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:rryan@cmh.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:info@siteman.wustl.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:unmcrsa@unmc.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:research@sncrf.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:research@sncrf.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:research@sncrf.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:research@sncrf.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:research@sncrf.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:cancer.research.nurse@dartmouth.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Christine.Kosmides@rwjbh.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:HallL@sjhmc.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:HSC-ClinicalTrialInfo@salud.unm.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:eskwak@montefiore.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:askroswell@roswellpark.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:nr2616@cumc.columbia.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:CancerTrials@nyulangone.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:CCTO@mssm.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:NCDV.ResearchRegulatory@HCAHealthcare.com?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:cancerclinicaltrials@med.unc.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:kashah@novanthealth.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:cancer@cchmc.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:TaussigResearch@ccf.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Melinda.Triplet@nationwidechildrens.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:PCIOncResearch@promedica.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:ou-clinical-trials@ouhsc.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:trials@ohsu.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Morgan_M.Horton@lvhn.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:HemonCCTrials@geisinger.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:CancerTrials@email.chop.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:jean.tersak@chp.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:hcc-clinical-trials@musc.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:OncologyClinicalTrialsSF@SanfordHealth.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:referralinfo@stjude.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:TXAUS-DL-SFCHemonc.research@ascension.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Crystal.DeLosSantos@dchstx.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:canceranswerline@UTSouthwestern.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:ranjan.bista@ttuhsc.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:CookChildrensResearch@cookchildrens.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:askmdanderson@mdanderson.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:burton@bcm.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:helpdesk@childrensoncologygroup.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:bridget.medina@christushealth.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:phoresearchoffice@uthscsa.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Vinod.GidvaniDiaz@hcahealthcare.com?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:rpo@uvm.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:uvacancertrials@hscmail.mcc.virginia.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Stephanie.VanBebber@inova.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:CCBDCresearch@chkd.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:CTOclinops@vcu.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:HopeBeginsHere@providence.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:research@multicare.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:Melissa.a.forouhar.mil@mail.mil?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:cancertrialsinfo@hsc.wvu.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:oncology.clinical.trials@marshfieldresearch.org?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "mailto:MACCCTO@mcw.edu?subject=NCT03533582, AHEP1531, Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Laboratory%20Biomarker%20Analysis", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Patient%20Observation", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Laboratory%20Biomarker%20Analysis", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Laboratory%20Biomarker%20Analysis", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Laboratory%20Biomarker%20Analysis", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Resection", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Laboratory%20Biomarker%20Analysis", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Resection", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Laboratory%20Biomarker%20Analysis", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Laboratory%20Biomarker%20Analysis", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Vincristine%20Sulfate", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Doxorubicin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Fluorouracil", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Laboratory%20Biomarker%20Analysis", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Resection", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Laboratory%20Biomarker%20Analysis", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Doxorubicin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Laboratory%20Biomarker%20Analysis", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Etoposide", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Doxorubicin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Laboratory%20Biomarker%20Analysis", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Vincristine%20Sulfate", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Doxorubicin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Irinotecan", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Laboratory%20Biomarker%20Analysis", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Doxorubicin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Patient%20Observation", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Laboratory%20Biomarker%20Analysis", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Doxorubicin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Laboratory%20Biomarker%20Analysis", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Doxorubicin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Sorafenib", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Laboratory%20Biomarker%20Analysis", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Gemcitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Doxorubicin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Oxaliplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Sorafenib", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Resection", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Children%27s%20Oncology%20Group", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=National%20Cancer%20Institute%20%28NCI%29", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Digestive%20System%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Histologic%20Type", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Site", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Neoplasms%2C%20Glandular%20and%20Epithelial", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Digestive%20System%20Neoplasms", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Liver%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Neoplasms%2C%20Complex%20and%20Mixed", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Neoplasms", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Carcinoma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Liver%20Neoplasms", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hepatoblastoma", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Physiological%20Effects%20of%20Drugs", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Molecular%20Mechanisms%20of%20Pharmacological%20Action", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Enzyme%20Inhibitors", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Antimetabolites%2C%20Antineoplastic", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Antimetabolites", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Antineoplastic%20Agents", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Immunosuppressive%20Agents", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Immunologic%20Factors", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Tubulin%20Modulators", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Antimitotic%20Agents", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Mitosis%20Modulators", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Antineoplastic%20Agents%2C%20Phytogenic", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Topoisomerase%20II%20Inhibitors", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Topoisomerase%20Inhibitors", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Dermatologic%20Agents", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Protein%20Kinase%20Inhibitors", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Antibiotics%2C%20Antineoplastic", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Keratolytic%20Agents", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Topoisomerase%20I%20Inhibitors", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Etoposide", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Etoposide%20phosphate", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Fluorouracil", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Sorafenib", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Oxaliplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Podophyllotoxin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Irinotecan", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Doxorubicin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Liposomal%20doxorubicin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Vincristine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Daunorubicin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Gemcitabine", "https://clinicaltrials.gov", "mailto:register@clinicaltrials.gov", "https://clinicaltrials.gov", "https://ichgcp.net/es/clinical-trials-registry/NCT05763173", "https://ichgcp.net/es/clinical-trials-registry/NCT05756660", "https://ichgcp.net/es/clinical-trials-registry/NCT05640960", "https://ichgcp.net/es/clinical-trials-registry/NCT05556642", "https://ichgcp.net/es/clinical-trials-registry/NCT05322187", "https://ichgcp.net/es/clinical-trials-registry/NCT05245123", "https://ichgcp.net/es/clinical-trials-registry/NCT05170282", "https://ichgcp.net/es/clinical-trials-registry/NCT04928677", "https://ichgcp.net/es/clinical-trials-registry/NCT04901702", "https://ichgcp.net/es/clinical-trials-registry/NCT04897321", "https://ichgcp.net/es/clinical-trials-registry/NCT05558904", "https://ichgcp.net/es/clinical-trials-registry/NCT05428852", "https://ichgcp.net/es/clinical-trials-registry/NCT05396859", "https://ichgcp.net/es/clinical-trials-registry/NCT05388773", "https://ichgcp.net/es/clinical-trials-registry/NCT05213585", "https://ichgcp.net/es/clinical-trials-registry/NCT05212428", "https://ichgcp.net/es/clinical-trials-registry/NCT05103904", "https://ichgcp.net/es/clinical-trials-registry/NCT05071859", "https://ichgcp.net/es/clinical-trials-registry/NCT05046080", "https://ichgcp.net/es/clinical-trials-registry/NCT04977024", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Center%2Bfor%2BIndustrial%2BTechnological%2BDevelopment%2Bof%2BSpain", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=SeeCure%2BLLC", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=European%2BSociety%2Bof%2BHuman%2BReproduction%2Band%2BEmbryology", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=AstraZeneca", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Medtronic%2BSurgical%2BTechnologies", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=National%2BCancer%2BInstitute%2B%2528NCI%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Jos%25C3%25A9phine%2BSOLTANI%252C%2BCardiology%2Bdepartment%252C%2BVersailles%2BHospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pediatric%2BOrthopaedic%2BSociety%2Bof%2BNorth%2BAmerica", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Mayo%2BClinic", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=M.D.%2BAnderson%2BCancer%2BCenter", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assistance%2BPublique%2B-%2BH%25C3%25B4pitaux%2Bde%2BParis", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=GlaxoSmithKline", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assiut%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Novartis%2BPharmaceuticals", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Cairo%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidade%2Bde%2BLisboa%252C%2BPortugal", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Kaneka%2BAmericas%2BHolding%2BInc.", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Orphanetics%2BPharma%2BEntwicklungs%2BGmbH", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pfizer", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidad%2Bdel%2BZulia", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Post-traumatic%2BAnosmia", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Esophageal%2BResection%2BCandidates", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hypertension", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stroke", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Postneoadjuvant%2BTherapy%2BStage%2BI%2BGastric%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Asthma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ankle%2BArthroplasty", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Cushing%2527s%2BSyndrome%2BI", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stage%2BI%2BGallbladder%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pain", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Prostate%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronary%2BArtery%2BDisease", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Breast%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Malignant%2BNeoplasm%2Bof%2BRespiratory%2Band%2BIntrathoracic%2BOrgan%2BCarcinoma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ultrasound%2BEvaluation", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Obesity", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Colon%2BMalignant%2BTumor", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=HIV%2BInfections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BAdrenal%2BCortical", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Depression", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Paclitaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Valacyclovir%2Barrow", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Oral%2BGlucose%2BGel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Teicoplanin%2BSandoz%2B200%2Bmg%2Bpowder%2Band%2Bsolvent%2Bfor%2Bsolution%2Bfor%2Binjection%2Bor%2Binfusion%2Bor%2Boral%2Bsolution.", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Docetaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cyclophosphamide", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Bevacizumab", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Injectafer", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Capecitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=MK-8521%2B100%25CE%25BCg", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Gemcitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Transplant%2B2%2BMelphalan", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Pilocarpine%2B1.25%2525%2BEye%2Bdrop", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Prednisone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=20mg%2BAzilsartan%2BTablets", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Alpelisib%2B150%2BMG%2BOral%2BTablet%2B%255BPiqray%255D", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Dexamethasone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Brimonidine%2Btartrate%2Bophthalmic%2Bsolution%2B0.025%2525%2B%2528n%2B%253D%2B56%2529", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/cro-list/country/chile", "https://ichgcp.net/es/cro-list/country/el_salvador", "https://ichgcp.net/es/cro-list/country/jamaica", "https://ichgcp.net/es/cro-list/country/lebanon", "https://ichgcp.net/es/cro-list/country/mali", "https://ichgcp.net/es/cro-list/country/mauritania", "https://ichgcp.net/es/cro-list/country/morocco", "https://ichgcp.net/es/cro-list/country/myanmar", "https://ichgcp.net/es/cro-list/country/netherlands", "https://ichgcp.net/es/cro-list/country/senegal", "https://ichgcp.net/es/cro-list/country/sri_lanka", "https://ichgcp.net/es/cro-list/country/trinidad_tobago", "https://ichgcp.net/es/cro-list/country/zimbabwe", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/cro-list/country/cameroon/company/sgs", "https://ichgcp.net/es/cro-list/country/cameroon", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/ord_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_cat", "https://ichgcp.net/es", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/about-us-our-mission", "https://ichgcp.net/es/sitemap", "https://ichgcp.net/es/contact-us", "https://ichgcp.net/es/feed", "/privacy", "/disclaimer", "https://ichgcp.net/da/clinical-trials-registry/NCT03533582", "https://ichgcp.net/de/clinical-trials-registry/NCT03533582", "https://ichgcp.net/clinical-trials-registry/NCT03533582", "https://ichgcp.net/es/clinical-trials-registry/NCT03533582", "https://ichgcp.net/fr/clinical-trials-registry/NCT03533582", "https://ichgcp.net/it/clinical-trials-registry/NCT03533582", "https://ichgcp.net/hu/clinical-trials-registry/NCT03533582", "https://ichgcp.net/nl/clinical-trials-registry/NCT03533582", "https://ichgcp.net/no/clinical-trials-registry/NCT03533582", "https://ichgcp.net/pl/clinical-trials-registry/NCT03533582", "https://ichgcp.net/pt/clinical-trials-registry/NCT03533582", "https://ichgcp.net/fi/clinical-trials-registry/NCT03533582", "https://ichgcp.net/sv/clinical-trials-registry/NCT03533582", "https://ichgcp.net/cs/clinical-trials-registry/NCT03533582", "https://ichgcp.net/ru/clinical-trials-registry/NCT03533582", "https://ichgcp.net/ja/clinical-trials-registry/NCT03533582", "https://ichgcp.net/zh/clinical-trials-registry/NCT03533582", "https://ichgcp.net/ko/clinical-trials-registry/NCT03533582", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf"]}